+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Drug Adherence Market: Focus on Smart Delivery Devices (Smart Inhalers, Injectors, Wearable Injectors, Pills) and Smart Accessories (Medication Dispensers, Pill Bottles / Boxes, Blister Packs)

  • ID: 4703795
  • Report
  • 450 Pages
  • Roots Analysis
1 of 4
Of the 4 Billion Annual Prescriptions Filled by the Retailers in the US, Approximately 50% are Not Taken by Patients in Accordance to Physicians’ Instructions

FEATURED COMPANIES

  • 3M
  • Capital Angels
  • Excell Partners
  • KCRise Fund
  • Novartis
  • SHL Group
  • MORE

Poor adherence to prescribed medications is a growing concern in the healthcare industry and is believed to be associated with negative health outcomes, inflated medical expenses, loss in productivity and, in certain cases, proves fatal as well. It has been estimated that, of the 4 billion annual prescriptions filled by the retailers in the US, approximately 50% are not taken by patients in accordance to physicians’ instructions. According to the US Centers for Disease Control and Prevention (CDC), failure to comply to prescribed treatment regimens has been identified as the cause of 125,000 premature deaths, up to 69% of all rehospitalizations, and results in approximately USD 100-300 billion worth of avoidable annual healthcare spending. Further, the US pharmaceutical industry alone is estimated to suffer a loss of approximately USD 188 billion per year, due to low adherence to prescribed medications.

Lack of compliance with therapy is particularly prevalent among elderly patients suffering from chronic clinical conditions, such as cardiovascular disorders, metabolic disorders (e.g., diabetes), neurological and central nervous system related disorders (e.g., multiple sclerosis and Parkinson’s disease) and respiratory disorders (e.g., asthma and chronic obstructive pulmonary disease). It is estimated that overall cost of treatment for non-adherent patients is at least twice as high as patients who adhere to recommended therapy regimens. Studies have demonstrated that every one percent improvement in medication adherence can help the US healthcare industry save up to USD 2 billion, resulting in an increase in pharmaceutical revenues by ~USD 4 billion. As a result, several strategies have been/are being developed by pharmaceutical developers and healthcare providers to improve medication adherence. Such initiatives have been strengthened owing to the availability of connected devices and other digital solutions, which allow patients/healthcare providers to closely monitor and improve drug adherence.

The ‘Global Drug Adherence Market: Focus on Smart Delivery Devices (Smart Inhalers, Injectors, Wearable Injectors, Pills) and Smart Accessories (Medication Dispensers, Pill Bottles / Boxes, Blister Packs)’ report features an extensive study of the current landscape and future outlook of the growing market for smart medication adherence devices that are either already commercialized or under development. This burgeoning field presently offers a lot of opportunities to innovation-driven start-ups and investors. Amongst other elements, the report features:

  • A discussion on the current market landscape of smart drug delivery devices for medication adherence (which include smart inhalers, smart injectors, smart wearable injectors and smart pills), featuring information on the developers, along with details on key product specifications, namely audio / visual reminders, connectivity features (USB connection, Bluetooth and / or cellular network), availability of companion mobile application(s) and / or web portal(s), data storage / cloud platform options, and availability of battery backup / rechargeable batteries.
  • A discussion on the current market landscape of smart accessory devices for medication adherence (including smart medication dispensers, smart pill bottles/caps, smart pillboxes, and smart blister packs), featuring information on the various developers, along with details on key product specifications. The section also presents a list of compliance packaging systems, along with information on their developers.
  • A summary of the various guidelines issued by regulatory authorities to govern the development and approval of combination products (drugs and smart devices) across different geographical regions.
  • Detailed profiles of some of the leading players in the industry (based on proprietary shortlisting criteria), highlighting a brief overview of the company, financial information (if available), details related to its products/offerings, clinical trial results, recent developments, and a comprehensive future outlook.
  • Detailed case studies on the most common chronic disease indications, featuring disease epidemiology, an overview of the economic burden imposed due to non-adherence to prescribed treatment regimens and a history of drug development efforts along with details on the evolution of delivery devices/strategies for improving therapy adherence.
  • A comprehensive competitiveness analysis of connected smart drug delivery systems and smart accessory systems on the basis of supplier power and key product specifications.
  • An analysis of funding and investments made in companies focused in this domain; the analysis covers information on seed financing, venture capital financing, debt financing, other equity financing and grants/awards received by these companies.
  • An analysis of the partnerships that have been forged between companies in the recent past, covering acquisitions, treatment optimization agreements, distribution agreements, manufacturing and supply agreements, product improvement agreements, product development agreements, product commercialization agreements, licensing agreements, service alliances and other relevant deals inked in the period 2010-2018. It also highlights the number of intercontinental and intracontinental deals signed in the aforementioned time period.
  • A list of standalone mobile applications that have been developed/are being developed to enable patients to adhere to prescribed medication regimens, along with the USFDA’s regulations related to such applications. It also includes details on the various articles/publications that have reported the results achieved by using mobile applications for improving medication adherence among patients.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on various parameters, such as target consumer segments, likely adoption rates, and expected pricing, we have provided an informed estimate on the likely evolution of the market in the short to mid-term and long-term, for the period 2018-2030. We have segmented the market by type of solution (smart drug delivery devices and smart accessory devices), type of product (smart inhalers, smart injectors, smart wearable injectors, smart pills, smart medication dispensers, smart pill bottles / caps and boxes, smart blister packs and others), therapeutic areas (metabolic disorders, cardiovascular disorders, neurological and central nervous system related disorders, respiratory disorders, and others), route of administration (oral, injectable, inhalable and others) and geography (North America, Europe, Asia-Pacific and rest of the world). To account for the uncertainties associated with the development of these novel therapies and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following individuals:

  • Bernard Vrijens (Chief Executive Officer, AARDEX Group)
  • Spencer Waugh (Chief Executive Officer, AceAge)
  • Josh Stein (Chief Executive Officer, AdhereTech)
  • Duilio Macchi (Chief Executive Officer, Amiko Digital Health)
  • Gaurav Patel (Chief Technical Officer, Cognita Labs)
  • Tina Valbh (Strategy and Business Development (Advisor), etectRx)
  • Jonathan Sacks (Chief Executive Officer and Chairman, PharmAdva)
  • Timo Heikkilä (Co-Founder and Chief Operating Officer, Popit Technologies)
  • Moore Greenberg (Founder, Wealth Taxi)
  • Anonymous (Small-sized company)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD unless otherwise specified.

Example Highlights:

  1. Currently, over 60 smart drug delivery devices are either commercially available or are under development for improving adherence to medication. More than 50% of these devices are smart inhalers or smart injectors. Examples of smart inhalers and smart injectors include (in alphabetical order, no selection criteria) 3M™ Intelligent Control Inhaler (3M), BETACONNECT™ (Medicom Innovation Partner), eMDI™ (H&T Presspart), Flexi-Q eMU-P and Flexi-Q eMU-C (Elcam Drug Delivery Device), GoCap (Common Sensing), Propeller (Propeller Health), SMARTTURBO™, SMARTTOUCH™ and SMARTTOUCH™ AV (Adherium), and SmartPilot and YpsoMate Smart (Ypsomed).
  2. In addition, there are close to 75 smart accessory devices that are either commercially available or are under development. Of these, over 40% are smart medication dispensers. Noteworthy examples of such products include (in alphabetical order, no selection criteria)Evondos® E300 (Evondos), HERO (HERO Health), Maya™ and Jon™ (MedMinder Systems), MedaCube (PharmaAdva) and Philips Medido (Philips), Pillo (Pillo Health) and SIMPLEMED+ (Vaica).
  3. Around 70% of the companies that are involved in the development of smart drug delivery systems and smart accessory systems are small-sized players/start-ups (having less than 50 employees). Examples of such companies include (in alphabetical order, no selection criteria) Aerobit Health, Airbrio, Arthur Health, Cognita Labs, CuePath Innovation, DayaMed, etectRx, MedMinder Systems, PharmRight, Popit, Portal Instruments, and Wealth Taxi.
  4. Over 50 compliance packaging systems are available to promote medication adherence among patients suffering from chronic clinical conditions; these include blister packs, pouches and dose cups. Companies engaged in the development of such products include (in alphabetical order, no selection criteria) Dispill-USA (Dispill® Multi-dose Packaging), Keystone Folding Box (Ecoslide-RX, Key-Pak® and Key-Pak Plus™), Omnicell (Opti-Pak™ and SureMed®), Parata Systems (Parata PASS Pack™) and TCGRx (AdherePac™ and AdhereCard™)
  5. Many standalone mobile applications are also available for improving compliance to prescribed therapeutic regimens. As of July 2018, over 200 such mobile applications, having user ratings of more than four, were available on Google Play Store. It is worth mentioning that more than 70% smart drug delivery and accessory devices that we came across have a supporting mobile application.
  6. Close to 180 partnerships have been inked between various stakeholders within the industry over the last few years; of these, over 100 collaborations were signed since 2016. Most of the deals that we came across were product development agreements (53%), signed between players to include new features in their products or advance their development programs. Examples of recently established deals include collaborations between Ypsomed and JDRF (August 2018), Adherium and Vitalus Health (August 2018), Amiko Digital Health and Luz Saúde (July 2018), Becton Dickinson and Helmer Scientific (June 2018), Common Sensing and Flex (May 2018), and Compliance Meds Technologies and Oracle Health Sciences (April 2018),
  7. Since 2001, nearly USD 2.5 billion has been invested in companies operating in the field of medication adherence. Interestingly, close to half of the total amount (USD 1.1 billion) was raised between 2015 and August 2018, indicating the rising interest of strategic investors in this domain. Examples of players that have managed to secure capital investments in multiple rounds include Proteus Digital Health, NantHealth, Tandem Diabetes Care, Propeller Health and Cellnovo.
  8. The drug adherence market is expected to grow at an annualized rate of more than 15.4% between 2018 and 2030. It is important to highlight that North America (primarily the US) and Europe currently capture the largest share of the overall market. This is followed by Asia-Pacific and the rest of the world. As the industry matures, we expect the market in Asia-Pacific to grow owing to the sizable user base in the region.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • 3M
  • Capital Angels
  • Excell Partners
  • KCRise Fund
  • Novartis
  • SHL Group
  • MORE

1. Preface
1.1. Scope of the Report
1.1. Research Methodology
1.2. Chapter Outlines

2. Executive Summary

3. Introduction
3.1. Medication Non-Adherence: A National Epidemic
3.2. Medication Adherence and its Measurement
3.3. Types of Medication Non-Adherence
3.3.1. Factors Contributing to Non-Adherence
3.3.2. Impact of Non-Adherence on Health of Patients and Healthcare Industry
3.4. Improving Medication Adherence
3.4.1. Traditional Interventions
3.4.2. Modern Interventions
3.4.2.1. Connected Devices
3.4.2.2. Mobile Applications
3.4.2.3. Gamification
3.4.2.4. Compliance Packaging
3.5. Key Initiatives to Improve Medication Adherence

4. Smart Drug Delivery Devices: Current Market Landscape
4.1. Chapter Overview
4.2. Smart Drug Delivery Devices: Overall Market Landscape
4.2.1. Distribution by Year of Establishment of Developers
4.2.2. Distribution by Geographical Location of Developers
4.2.3. Distribution by Size of Developers
4.2.4. Distribution by Type of Devices
4.2.5. Distribution by Mode of Drug Delivery
4.2.6. Distribution by Key Device Specifications
4.2.6.1. Audio / Visual Reminders
4.2.6.2. Connectivity (USB, Bluetooth, or Cellular)
4.2.6.3. Companion Mobile Application
4.2.6.4. Companion Web Portal
4.2.6.5. Data Storage / Cloud Platform
4.2.6.6. Rechargeable Battery / Battery Backup
4.2.7. Key Players
4.2.8. Smart Inhalers
4.2.8.1. Distribution by Year of Establishment of Developers
4.2.8.2. Distribution by Geographical Location of Developers
4.2.8.3. Distribution by Size of Developers
4.2.8.4. Distribution by Key Device Specifications
4.2.9. Smart Injectors
4.2.9.1. Distribution by Year of Establishment of Developers
4.2.9.2. Distribution by Geographical Location of Developers
4.2.9.3. Distribution by Size of Developers
4.2.9.4. Distribution by Key Device Specifications
4.2.10. Smart Wearable Injectors
4.2.10.1. Distribution by Year of Establishment of Developers
4.2.10.2. Distribution by Geographical Location of Developers
4.2.10.3. Distribution by Size of Developers
4.2.10.4. Distribution by Key Device Specifications
4.2.11. Smart Pills / Other Smart Devices
4.2.11.1. Distribution by Year of Establishment of Developers
4.2.11.2. Distribution by Geographical Location of Developers
4.2.11.3. Distribution by Size of Developers
4.2.11.4. Distribution by Key Device Specifications

5. Smart Accessory Devices And Packaging Systems: Current Market Landscape
5.1. Chapter Overview
5.2. Smart Accessory Devices: Overall Market Landscape
5.2.1. Distribution by Year of Establishment of Developers
5.2.2. Distribution by Geographical Location of Developers
5.2.3. Distribution by Size of Developer
5.2.4. Distribution by Type of Devices
5.2.5. Distribution by Key Device Specifications
5.2.5.1. Audio / Visual Reminders
5.2.5.2. Connectivity (USB, Bluetooth, Wi-Fi, or Cellular)
5.2.5.3. Companion Mobile Application
5.2.5.4. Companion Web Portal
5.2.5.5. Data Storage / Cloud Platform
5.2.5.6. Rechargeable Battery / Battery Backup
5.2.6. Key Players
5.2.7. Smart Medication Dispensers
5.2.7.1. Distribution by Year of Establishment of Developers
5.2.7.2. Distribution by Geographical Location of Developers
5.2.7.3. Distribution by Size of Developers
5.2.7.4. Distribution by Key Device Specifications
5.2.8. Smart Pill Bottles / Caps
5.2.8.1. Distribution by Year of Establishment of Developers
5.2.8.2. Distribution by Geographical Location of Developers
5.2.8.3. Distribution by Size of Developers
5.2.8.4. Distribution by Key Device Specifications
5.2.9. Smart Pill Boxes
5.2.9.1. Distribution by Year of Establishment of Developers
5.2.9.2. Distribution by Geographical Location of Developers
5.2.9.3. Distribution by Size of Developers
5.2.9.4. Distribution by Key Device Specifications
5.2.10. Smart Blister Packs
5.2.10.1. Distribution by Year of Establishment of Developers
5.2.10.2. Distribution by Geographical Location of Developers
5.2.10.3. Distribution by Size of Developers
5.2.10.4. Distribution by Key Device Specifications
5.2.11. Other Smart Devices
5.2.11.1. Distribution by Year of Establishment of Developers
5.2.11.2. Distribution by Geographical Location of Developers
5.2.11.3. Distribution by Size of Developers
5.2.11.4. Distribution by Key Device Specifications
5.3. Compliance Packaging Systems: Overall Market Landscape
5.3.1. Distribution by Geographical Location of Developers
5.3.2. Distribution by Size of Developers
5.3.3. Distribution by Type of Packaging System
5.3.4. Distribution by Key Specifications
5.3.4.1. Distribution by Number of Doses per Pack
5.3.4.2. Distribution by Availability of Other Key Features

6. Regulatory Landscape For Connected Drug Delivery Systems
6.1. Chapter Overview
6.2. North America
6.2.1. Regulatory Approval of Combination Products in the US
6.2.1.1. Overview
6.2.1.2. Historical Background
6.2.1.3. Regulatory Bodies and their Role in Product Approval
6.2.2. Regulatory Approval of Combination Products in Canada
6.2.2.1. Overview
6.2.2.2. Regulatory Bodies and Their Role in Product Approval
6.3. Europe
6.3.1. Regulatory Approval of Combination Products in Europe
6.3.1.1. Overview
6.3.1.2. Regulatory Bodies and Their Role in Product Approval
6.4. Latin America
6.4.1. Regulatory Approval of Combination Products in Brazil
6.4.1.1. Overview
6.4.1.2. Regulatory Bodies and Their Role in Product Approval
6.4.2. Regulatory Approval of Combination Products in Mexico
6.4.2.1. Overview
6.4.2.2. Regulatory Bodies and Their Role in Product Approval
6.4.3. Regulations of Combination Products in Argentina
6.4.3.1. Overview
6.4.3.2. Regulatory Bodies and Their Role in Product Approval
6.5. Asia-Pacific
6.5.1. Regulatory Approval of Combination Products in Japan
6.5.1.1. Overview
6.5.1.2. Regulatory Bodies and Their Role in Product Approval
6.5.2. Regulation of Combination Products in South Korea
6.5.2.1. Overview
6.5.2.2. Regulatory Bodies and Their Role in Product Approval
6.5.3. Regulatory Approval of Combination Products in Australia
6.5.3.1. Overview
6.5.3.2. Regulatory Bodies and Their Role in Product Approval
6.5.4. Regulatory Approval of Combination Products in China
6.5.4.1. Overview
6.5.4.2. Regulatory Bodies and Their Role in Product Approval
6.5.5. Regulations of Combination Products in India
6.5.5.1. Overview
6.5.5.2. Regulatory Bodies and Their Role in Product Approval
6.6. Middle East
6.6.1. Regulation of Combination Products in Saudi Arabia
6.6.1.1. Overview
6.6.1.2. Regulatory Bodies and Their Role in Product Approval
6.6.2. Regulation of Combination Products in United Arab Emirates
6.6.2.1. Overview
6.6.2.2. Regulatory Bodies and Their Role in Product Approval
6.7. Connected Devices: Demonstrating Safety, Effectiveness and Performance
6.8. Connected Devices: Ensuring Security of Data Captured

7. Drug Delivery Devices: Company Profiles
7.1. Chapter Overview
7.2. Adherium
7.2.1. Company Overview
7.2.2. Financial Information
7.2.3. Product Portfolio
7.2.4. Research Studies and Scientific Evidence
7.2.5. Recent Developments and Future Outlook
7.3. BIOCORP
7.3.1. Company Overview
7.3.2. Financial Information
7.3.3. Product Portfolio
7.3.4. Recent Developments and Future Outlook
7.4. nGageIT Digital Health
7.4.1. Company Overview
7.4.2. Product Portfolio
7.4.3. Recent Developments and Future Outlook
7.5. Proteus Digital Health
7.5.1. Company Overview
7.5.2. Product Portfolio
7.5.3. Research Studies and Scientific Evidence
7.5.4. Recent Developments and Future Outlook
7.6. SOOIL Development
7.6.1. Company Overview
7.6.2. Product Portfolio
7.6.3. Recent Developments and Future Outlook
7.7. Ypsomed
7.7.1. Company Overview
7.7.2. Financial Information
7.7.3. Product Portfolio
7.7.4. Recent Developments and Future Outlook

8. Accessory Devices: Company Profiles
8.1. Chapter Overview
8.2. AARDEX Group
8.2.1. Company Overview
8.2.2. Product Portfolio
8.2.3. Recent Developments and Future Outlook
8.3. Information Mediary
8.3.1. Company Overview
8.3.2. Product Portfolio
8.3.3. Recent Developments and Future Outlook
8.4. MedMinder Systems
8.4.1. Company Overview
8.4.2. Product Portfolio
8.4.3. Recent Developments and Future Outlook
8.5. Philips
8.5.1. Company Overview
8.5.2. Financial Information
8.5.3. Product Portfolio
8.5.4. Research Studies and Scientific Evidence
8.5.5. Recent Developments and Future Outlook
8.6. Tinylogics
8.6.1. Company Overview
8.6.2. Product Portfolio
8.6.3. Recent Developments and Future Outlook
8.7. Vaica
8.7.1. Company Overview
8.7.2. Product Portfolio
8.7.3. Research Studies and Scientific Evidence
8.7.4. Recent Developments and Future Outlook

9. Case Studies
9.1. Chapter Overview
9.2. Case Study I: Diabetes
9.2.1. Disease Description
9.2.2. Disease Statistics
9.2.3. Economic Burden due to Non-Adherence
9.2.4. Evolution of Drug Delivery / Connected Devices for Improving Adherence
9.3. Case Study II: Asthma
9.3.1. Disease Overview
9.3.2. Disease Statistics
9.3.3. Economic Burden due to Non-Adherence
9.3.4. Evolution of Drug Delivery / Connected Devices for Improving Adherence
9.4. Case Study III: Rheumatoid Arthritis
9.4.1. Disease Overview
9.4.2. Disease Statistics
9.4.3. Economic Burden due to Non-Adherence
9.4.4. Evolution of Drug Delivery / Connected Devices for Improving Adherence

10. Product Competitiveness Analysis
10.1. Chapter Overview
10.2. Methodology
10.2.1. Key Parameters and Methodology
10.3. Overall Product Competitiveness Analysis
10.3.1. Product Competitiveness Analysis for Smart Medication Dispensers
10.3.2. Product Competitiveness Analysis for Smart Pill Packaging Systems
10.3.3. Product Competitiveness Analysis for Smart Inhalers
10.3.4. Product Competitiveness Analysis for Smart Injectors
10.3.5. Product Competitiveness Analysis for Smart Wearable Injectors

11. Funding and Investment Analysis
11.1. Chapter Overview
11.2. Types of Funding
11.3. Drug Adherence Enhancement Market: Funding and Investment Analysis
11.3.1. Analysis by Number of Instances
11.3.2. Analysis by Amount Invested
11.3.3. Analysis by Type of Funding
11.3.4. Analysis by Number of Funding Instances and Amount Invested in Different Types of Devices
11.3.5. Most Active Players
11.3.6. Most Active Investors
11.4. Concluding Remarks

12. Partnerships and Collaborations
12.1. Chapter Overview
12.2. Partnership Models
12.3. Drug Adherence Enhancement Market: List of Partnerships and Collaborations
12.3.1. Analysis by Year of Partnership
12.3.2. Analysis by Type of Partnership
12.3.3. Analysis by Geographical Activity
12.3.4. Most Active Players: Analysis by Number of Partnerships
12.3.5. Concluding Remarks

13. Medication Adherence With Mobile Applications
13.1. Chapter Overview
13.2. The Increasing Trend of Mobile Applications in Healthcare Industry
13.3. USFDA Regulations for Mobile Medical Applications
13.4. List of Mobile Applications for Improving Medication Adherence
13.5. Medication Adherence with Mobile Applications: Clinical Research Evidence
13.5.1. Distribution by Therapeutic Area

14. Market Forecast
14.1. Chapter Overview
14.2. Forecast Methodology and Key Assumptions
14.3. Global Drug Adherence Enhancement Market
14.3.1. Global Drug Adherence Enhancement Market, 2018-2030 (By Value)
14.3.1.1. Drug Adherence Enhancement Market for Smart Drug Delivery Devices, 2018-2030 (By Value)
14.3.1.2. Drug Adherence Enhancement Market for Smart Accessory Devices, 2018-2030 (By Value)
14.3.1.3. Drug Adherence Enhancement Market for Other Type of Devices, 2018-2030 (By Value)
14.3.2. Global Drug Adherence Enhancement Market, 2018-2030 (By Volume)
14.3.2.1. Drug Adherence Enhancement Market for Smart Drug Delivery Devices, 2018-2030 (By Volume)
14.3.2.2. Drug Adherence Enhancement Market for Smart Accessory Devices, 2018-2030 (By Volume)
14.3.2.3. Drug Adherence Enhancement Market for Other Type of Devices, 2018-2030 (By Volume)
14.4. Global Drug Adherence Enhancement Market: Distribution by Geography, 2018-2030 (By Value)
14.4.1. Drug Adherence Enhancement Market in North America, 2018-2030 (By Value)
14.4.2. Drug Adherence Enhancement Market in Europe, 2018-2030 (By Value)
14.4.3. Drug Adherence Enhancement Market in Asia-Pacific, 2018-2030 (By Value)
14.4.4. Drug Adherence Enhancement Market in Rest of the World, 2018-2030 (By Value)
14.5. Global Drug Adherence Enhancement Market: Distribution by Type of Product and Geography (By Value)
14.5.1. Drug Adherence Enhancement Market for Smart Inhalers, 2018-2030 (By Value)
14.5.1.1. Drug Adherence Enhancement Market for Smart Inhalers in North America, 2018-2030 (By Value)
14.5.1.2. Drug Adherence Enhancement Market for Smart Inhalers in Europe, 2018-2030 (By Value)
14.5.1.3. Drug Adherence Enhancement Market for Smart Inhalers in Asia-Pacific, 2018-2030 (By Value)
14.5.1.4. Drug Adherence Enhancement Market for Smart Inhalers in Rest of the World, 2018-2030 (By Value)
14.5.2. Drug Adherence Enhancement Market for Smart Injectors, 2018-2030 (By Value)
14.5.2.1. Drug Adherence Enhancement Market for Smart Injectors in North America, 2018-2030 (By Value)
14.5.2.2. Drug Adherence Enhancement Market for Smart Injectors in Europe, 2018-2030 (By Value)
14.5.2.3. Drug Adherence Enhancement Market for Smart Injectors in Asia-Pacific, 2018-2030 (By Value)
14.5.2.4. Drug Adherence Enhancement Market for Smart Injectors in Rest of the World, 2018-2030 (By Value)
14.5.3. Drug Adherence Enhancement Market for Smart Wearable Injectors, 2018-2030 (By Value)
14.5.3.1. Drug Adherence Enhancement Market for Smart Wearable Injectors in North America, 2018-2030 (By Value)
14.5.3.2. Drug Adherence Enhancement Market for Smart Wearable Injectors in Europe, 2018-2030 (By Value)
14.5.3.3. Drug Adherence Enhancement Market for Smart Wearable Injectors in Asia-Pacific, 2018-2030 (By Value)
14.5.3.4. Drug Adherence Enhancement Market for Smart Wearable Injectors in Rest of the World, 2018-2030 (By Value)
14.5.4. Drug Adherence Enhancement Market for Smart Pills, 2018-2030 (By Value)
14.5.4.1. Drug Adherence Enhancement Market for Smart Pills in North America, 2018-2030 (By Value)
14.5.4.2. Drug Adherence Enhancement Market for Smart Pills in Europe, 2018-2030 (By Value)
14.5.4.3. Drug Adherence Enhancement Market for Smart Pills in Asia-Pacific, 2018-2030 (By Value)
14.5.4.4. Drug Adherence Enhancement Market for Smart Pills in Rest of the World, 2018-2030 (By Value)
14.5.5. Drug Adherence Enhancement Market for Smart Medication Dispensers, 2018-2030 (By Value)
14.5.5.1. Drug Adherence Enhancement Market for Smart Medication Dispensers in North America, 2018-2030 (By Value)
14.5.5.2. Drug Adherence Enhancement Market for Smart Medication Dispensers in Europe, 2018-2030 (By Value)
14.5.5.3. Drug Adherence Enhancement Market for Smart Medication Dispensers in Asia-Pacific, 2018-2030 (By Value)
14.5.5.4. Drug Adherence Enhancement Market for Smart Medication Dispensers in Rest of the World, 2018-2030 (By Value)
14.5.6. Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes, 2018-2030 (By Value)
14.5.6.1. Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in North America, 2018-2030 (By Value)
14.5.6.2. Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in Europe, 2018-2030 (By Value)
14.5.6.3. Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in Asia-Pacific, 2018-2030 (By Value)
14.5.6.4. Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in Rest of the World, 2018-2030 (By Value)
14.5.7. Drug Adherence Enhancement Market for Smart Blister Packs, 2018-2030 (By Value)
14.5.7.1. Drug Adherence Enhancement Market for Smart Blister Packs in North America, 2018-2030 (By Value)
14.5.7.2. Drug Adherence Enhancement Market for Smart Blister Packs in Europe, 2018-2030 (By Value)
14.5.7.3. Drug Adherence Enhancement Market for Smart Blister Packs in Asia-Pacific, 2018-2030 (By Value)
14.5.7.4. Drug Adherence Enhancement Market for Smart Blister Packs in Rest of the World, 2018-2030 (By Value)
14.5.8. Drug Adherence Enhancement Market for Other Type of Products, 2018-2030 (By Value)
14.5.8.1. Drug Adherence Enhancement Market for Other Type of Products in North America, 2018-2030 (By Value)
14.5.8.2. Drug Adherence Enhancement Market for Other Type of Products in Europe, 2018-2030 (By Value)
14.5.8.3. Drug Adherence Enhancement Market for Other Type of Products in Asia-Pacific, 2018-2030 (By Value)
14.5.8.4. Drug Adherence Enhancement Market for Other Type of Products in Rest of the World, 2018-2030 (By Value)
14.6. Global Drug Adherence Enhancement Market: Distribution by Type of Product (By Volume)
14.6.1. Drug Adherence Enhancement Market for Smart Inhalers, 2018-2030 (By Volume)
14.6.1.1. Drug Adherence Enhancement Market for Smart Inhalers in North America, 2018-2030 (By Volume)
14.6.1.2. Drug Adherence Enhancement Market for Smart Inhalers in Europe, 2018-2030 (By Volume)
14.6.1.3. Drug Adherence Enhancement Market for Smart Inhalers in Asia-Pacific, 2018-2030 (By Volume)
14.6.1.4. Drug Adherence Enhancement Market for Smart Inhalers in Rest of the World, 2018-2030 (By Volume)
14.6.2. Drug Adherence Enhancement Market for Smart Injectors, 2018-2030 (By Volume)
14.6.2.1. Drug Adherence Enhancement Market for Smart Injectors in North America, 2018-2030 (By Volume)
14.6.2.2. Drug Adherence Enhancement Market for Smart Injectors in Europe, 2018-2030 (By Volume)
14.6.2.3. Drug Adherence Enhancement Market for Smart Injectors in Asia-Pacific, 2018-2030 (By Volume)
14.6.2.4. Drug Adherence Enhancement Market for Smart Injectors in Rest of the World, 2018-2030 (By Volume)
14.6.3. Drug Adherence Enhancement Market for Smart Wearable Injectors, 2018-2030 (By Volume)
14.6.3.1. Drug Adherence Enhancement Market for Smart Wearable Injectors in North America, 2018-2030 (By Volume)
14.6.3.2. Drug Adherence Enhancement Market for Smart Wearable Injectors in Europe, 2018-2030 (By Volume)
14.6.3.3. Drug Adherence Enhancement Market for Smart Wearable Injectors in Asia-Pacific, 2018-2030 (By Volume)
14.6.3.4. Drug Adherence Enhancement Market for Smart Wearable Injectors in Rest of the World, 2018-2030 (By Volume)
14.6.4. Drug Adherence Enhancement Market for Smart Pills, 2018-2030 (By Volume)
14.6.4.1. Drug Adherence Enhancement Market for Smart Pills in North America, 2018-2030 (By Volume)
14.6.4.2. Drug Adherence Enhancement Market for Smart Pills in Europe, 2018-2030 (By Volume)
14.6.4.3. Drug Adherence Enhancement Market for Smart Pills in Asia-Pacific, 2018-2030 (By Volume)
14.6.4.4. Drug Adherence Enhancement Market for Smart Pills in Rest of the World, 2018-2030 (By Volume)
14.6.5. Drug Adherence Enhancement Market for Smart Medication Dispensers, 2018-2030 (By Volume)
14.6.5.1. Drug Adherence Enhancement Market for Smart Medication Dispensers in North America, 2018-2030 (By Volume)
14.6.5.2. Drug Adherence Enhancement Market for Smart Medication Dispensers in Europe, 2018-2030 (By Volume)
14.6.5.3. Drug Adherence Enhancement Market for Smart Medication Dispensers in Asia-Pacific, 2018-2030 (By Volume)
14.6.5.4. Drug Adherence Enhancement Market for Smart Medication Dispensers in Rest of the World, 2018-2030 (By Volume)
14.6.6. Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes, 2018-2030 (By Volume)
14.6.6.1. Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in North America, 2018-2030 (By Volume)
14.6.6.2. Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in Europe, 2018-2030 (By Volume)
14.6.6.3. Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in Asia-Pacific, 2018-2030 (By Volume)
14.6.6.4. Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in Rest of the World, 2018-2030 (By Volume)
14.6.7. Drug Adherence Enhancement Market for Smart Blister Packs, 2018-2030 (By Volume)
14.6.7.1. Drug Adherence Enhancement Market for Smart Blister Packs in North America, 2018-2030 (By Volume)
14.6.7.2. Drug Adherence Enhancement Market for Smart Blister Packs in Europe, 2018-2030 (By Volume)
14.6.7.3. Drug Adherence Enhancement Market for Smart Blister Packs in Asia-Pacific, 2018-2030 (By Volume)
14.6.7.4. Drug Adherence Enhancement Market for Smart Blister Packs in Rest of the World, 2018-2030 (By Volume)
14.6.8. Drug Adherence Enhancement Market for Other Type of Products, 2018-2030 (By Volume)
14.6.8.1. Drug Adherence Enhancement Market for Other Type of Products in North America, 2018-2030 (By Volume)
14.6.8.2. Drug Adherence Enhancement Market for Other Type of Products in Europe, 2018-2030 (By Volume)
14.6.8.3. Drug Adherence Enhancement Market for Other Type of Products in Asia-Pacific, 2018-2030 (By Volume)
14.6.8.4. Drug Adherence Enhancement Market for Other Type of Products in Rest of the World, 2018-2030 (By Volume)
14.7. Global Drug Adherence Enhancement Market: Distribution by Therapeutic Area and Geography (By Value)
14.7.1. Drug Adherence Enhancement Market for Metabolic Disorders (By Value)
14.7.1.1. Drug Adherence Enhancement Market for Metabolic Disorders in North America, 2018-2030 (By Value)
14.7.1.2. Drug Adherence Enhancement Market for Metabolic Disorders in Europe, 2018-2030 (By Value)
14.7.1.3. Drug Adherence Enhancement Market for Metabolic Disorders in Asia-Pacific, 2018-2030 (By Value)
14.7.1.4. Drug Adherence Enhancement Market for Metabolic Disorders in Rest of the World, 2018-2030 (By Value)
14.7.2. Drug Adherence Enhancement Market for Cardiovascular Disorders (By Value)
14.7.2.1. Drug Adherence Enhancement Market for Cardiovascular Disorders in North America, 2018-2030 (By Value)
14.7.2.2. Drug Adherence Enhancement Market for Cardiovascular Disorders in Europe, 2018-2030 (By Value)
14.7.2.3. Drug Adherence Enhancement Market for Cardiovascular Disorders in Asia-Pacific, 2018-2030 (By Value)
14.7.2.4. Drug Adherence Enhancement Market for Cardiovascular Disorders in Rest of the World, 2018-2030 (By Value)
14.7.3. Drug Adherence Enhancement Market for Respiratory Disorders (By Value)
14.7.3.1. Drug Adherence Enhancement Market for Respiratory Disorders in North America, 2018-2030 (By Value)
14.7.3.2. Drug Adherence Enhancement Market for Respiratory Disorders in Europe, 2018-2030 (By Value)
14.7.3.3. Drug Adherence Enhancement Market for Respiratory Disorders in Asia-Pacific, 2018-2030 (By Value)
14.7.3.4. Drug Adherence Enhancement Market for Respiratory Disorders in Rest of The World, 2018-2030 (By Value)
14.7.4. Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders (By Value)
14.7.4.1. Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in North America, 2018-2030 (By Value)
14.7.4.2. Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in Europe, 2018-2030 (By Value)
14.7.4.3. Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in Asia-Pacific, 2018-2030 (By Value)
14.7.4.4. Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in Rest of the World, 2018-2030 (By Value)
14.7.5. Drug Adherence Enhancement Market for Other Disorders (By Value)
14.7.5.1. Drug Adherence Enhancement Market for Other Disorders in North America, 2018-2030 (By Value)
14.7.5.2. Drug Adherence Enhancement Market for Other Disorders in Europe, 2018-2030 (By Value)
14.7.5.3. Drug Adherence Enhancement Market for Other Disorders in Asia-Pacific, 2018-2030 (By Value)
14.7.5.4. Drug Adherence Enhancement Market for Other Disorders in Rest of the World, 2018-2030 (By Value)
14.8. Global Drug Adherence Enhancement Market: Distribution by Therapeutic Area and Geography (By Volume)
14.8.1. Drug Adherence Enhancement Market for Metabolic Disorders (By Volume)
14.8.1.1. Drug Adherence Enhancement Market for Metabolic Disorders in North America, 2018-2030 (By Volume)
14.8.1.2. Drug Adherence Enhancement Market for Metabolic Disorders in Europe, 2018-2030 (By Volume)
14.8.1.3. Drug Adherence Enhancement Market for Metabolic Disorders in Asia-Pacific, 2018-2030 (By Volume)
14.8.1.4. Drug Adherence Enhancement Market for Metabolic Disorders in Rest of the World, 2018-2030 (By Volume)
14.8.2. Drug Adherence Enhancement Market for Cardiovascular Disorders (By Volume)
14.8.2.1. Drug Adherence Enhancement Market for Cardiovascular Disorders in North America, 2018-2030 (By Volume)
14.8.2.2. Drug Adherence Enhancement Market for Cardiovascular Disorders in Europe, 2018-2030 (By Volume)
14.8.2.3. Drug Adherence Enhancement Market for Cardiovascular Disorders in Asia-Pacific, 2018-2030 (By Volume)
14.8.2.4. Drug Adherence Enhancement Market for Cardiovascular Disorders in Rest of the World, 2018-2030 (By Volume)
14.8.3. Drug Adherence Enhancement Market for Respiratory Disorders (By Volume)
14.8.3.1. Drug Adherence Enhancement Market for Respiratory Disorders in North America, 2018-2030 (By Volume)
14.8.3.2. Drug Adherence Enhancement Market for Respiratory Disorders in Europe, 2018-2030 (By Volume)
14.8.3.3. Drug Adherence Enhancement Market for Respiratory Disorders in Asia-Pacific, 2018-2030 (By Volume)
14.8.3.4. Drug Adherence Enhancement Market for Respiratory Disorders in Rest of The World, 2018-2030 (By Volume)
14.8.4. Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders (By Volume)
14.8.4.1. Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in North America, 2018-2030 (By Volume)
14.8.4.2. Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in Europe, 2018-2030 (By Volume)
14.8.4.3. Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in Asia-Pacific, 2018-2030 (By Volume)
14.8.4.4. Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in Rest of the World, 2018-2030 (By Volume)
14.8.5. Drug Adherence Enhancement Market for Other Disorders (By Volume)
14.8.5.1. Drug Adherence Enhancement Market for Other Disorders in North America, 2018-2030 (By Volume)
14.8.5.2. Drug Adherence Enhancement Market for Other Disorders in Europe, 2018-2030 (By Volume)
14.8.5.3. Drug Adherence Enhancement Market for Other Disorders in Asia-Pacific, 2018-2030 (By Volume)
14.8.5.4. Drug Adherence Enhancement Market for Other Disorders in Rest of the World, 2018-2030 (By Volume)
14.9. Global Drug Adherence Enhancement Market: Distribution by Route of Drug Administration and Geography (By Value)
14.9.1. Drug Adherence Enhancement Market for Products Intended for Oral Medications, 2018-2030 (By Value)
14.9.1.1. Drug Adherence Enhancement Market for Products Intended for Oral Medications in North America, 2018-2030 (By Value)
14.9.1.2. Drug Adherence Enhancement Market for Products Intended for Oral Medications in Europe, 2018-2030 (By Value)
14.9.1.3. Drug Adherence Enhancement Market for Products Intended for Oral Medications in Asia-Pacific, 2018-2030 (By Value)
14.9.1.4. Drug Adherence Enhancement Market for Products Intended for Oral Medications in Rest of the World, 2018-2030 (By Value)
14.9.2. Drug Adherence Enhancement Market for Products Intended for Injectables, 2018-2030 (By Value)
14.9.2.1. Drug Adherence Enhancement Market for Products Intended for Injectables in North America, 2018-2030 (By Value)
14.9.2.2. Drug Adherence Enhancement Market for Products Intended for Injectables in Europe, 2018-2030 (By Value)
14.9.2.3. Drug Adherence Enhancement Market for Products Intended for Injectables in Asia-Pacific, 2018-2030 (By Value)
14.9.2.4. Drug Adherence Enhancement Market for Products Intended for Injectables in Rest of the World, 2018-2030 (By Value)
14.9.3. Drug Adherence Enhancement Market for Products Intended for Inhalable Medications, 2018-2030 (By Value)
14.9.3.1. Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in North America, 2018-2030 (By Value)
14.9.3.2. Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in Europe, 2018-2030 (By Value)
14.9.3.3. Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in Asia-Pacific, 2018-2030 (By Value)
14.9.3.4. Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in Rest of the World, 2018-2030 (By Value)
14.9.4. Drug Adherence Enhancement Market for Products Intended for Other Medications, 2018-2030 (By Value)
14.9.4.1. Drug Adherence Enhancement Market for Products Intended for Other Medications in North America, 2018-2030 (By Value)
14.9.4.2. Drug Adherence Enhancement Market for Products Intended for Other Medications in Europe, 2018-2030 (By Value)
14.9.4.3. Drug Adherence Enhancement Market for Products Intended for Other Medications in Asia-Pacific, 2018-2030 (By Value)
14.9.4.4. Drug Adherence Enhancement Market for Products Intended for Other Medications in Rest of the World, 2018-2030 (By Value)
14.10. Global Drug Adherence Enhancement Market: Distribution by Route of Drug Administration and Geography (By Volume)
14.10.1. Drug Adherence Enhancement Market for Products Intended for Oral Medications, 2018-2030 (By Volume)
14.10.1.1. Drug Adherence Enhancement Market for Products Intended for Oral Medications in North America, 2018-2030 (By Volume)
14.10.1.2. Drug Adherence Enhancement Market for Products Intended for Oral Medications in Europe, 2018-2030 (By Volume)
14.10.1.3. Drug Adherence Enhancement Market for Products Intended for Oral Medications in Asia-Pacific, 2018-2030 (By Volume)
14.10.1.4. Drug Adherence Enhancement Market for Products Intended for Oral Medications in Rest of the World, 2018-2030 (By Volume)
14.10.2. Drug Adherence Enhancement Market for Products Intended for Injectables, 2018-2030 (By Volume)
14.10.2.1. Drug Adherence Enhancement Market for Products Intended for Injectables in North America, 2018-2030 (By Volume)
14.10.2.2. Drug Adherence Enhancement Market for Products Intended for Injectables in Europe, 2018-2030 (By Volume)
14.10.2.3. Drug Adherence Enhancement Market for Products Intended for Injectables in Asia-Pacific, 2018-2030 (By Volume)
14.10.2.4. Drug Adherence Enhancement Market for Products Intended for Injectables in Rest of the World, 2018-2030 (By Volume)
14.10.3. Drug Adherence Enhancement Market for Products Intended for Inhalable Medications, 2018-2030 (By Volume)
14.10.3.1. Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in North America, 2018-2030 (By Volume)
14.10.3.2. Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in Europe, 2018-2030 (By Volume)
14.10.3.3. Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in Asia-Pacific, 2018-2030 (By Volume)
14.10.3.4. Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in Rest of the World, 2018-2030 (By Volume)
14.10.4. Drug Adherence Enhancement Market for Products Intended for Other Medications, 2018-2030 (By Volume)
14.10.4.1. Drug Adherence Enhancement Market for Products Intended for Other Medications in North America, 2018-2030 (By Volume)
14.10.4.2. Drug Adherence Enhancement Market for Products Intended for Other Medications in Europe, 2018-2030 (By Volume)
14.10.4.3. Drug Adherence Enhancement Market for Products Intended for Other Medications in Asia-Pacific, 2018-2030 (By Volume)
14.10.4.4. Drug Adherence Enhancement Market for Products Intended for Other Medications in Rest of the World, 2018-2030 (By Volume)

15. Conclusion
15.1. Poor Adherence to Therapies for the Treatment of Chronic Disorders Poses a Significant Economic Burden on the Healthcare Industry
15.2. Presently, Several Players are Developing IoT-Enabled / Connected Devices for Improving Medication Adherence; Majority of these are Small-sized Companies based in the US
15.3. Increasing Financial Support from Various Investors is Indicative of Future Opportunities related to Novel Strategies for Medication Adherence Improvement
15.4. Players have Entered into Strategic Collaborations to Support the Development of their Smart Products
15.5. Availability of Standalone, as well as Companion Mobile Applications, is Expected to Provide a More Integrated Approach for Improving Adherence
15.6. With Increasing Focus on Improving Therapy Efficacy and Alleviating Healthcare Burden, the Overall Market is Anticipated to Witness Steady Growth

16. Executive Insights
16.1. Chapter Overview
16.2. AARDEX Group
16.2.1. Company Snapshot
16.2.2. Interview Transcript: Bernard Vrijens, Chief Executive Officer
16.3. AceAge
16.3.1. Company Snapshot
16.3.2. Interview Transcript: Spencer Waugh, Chief Executive Officer
16.4. AdhereTech
16.4.1. Company Snapshot
16.4.2. Interview Transcript: Josh Stein, Chief Executive Officer
16.5. Amiko Digital Health
16.5.1. Company Snapshot
16.5.2. Interview Transcript: Duilio Macchi, Chief Executive Officer
16.6. Cognita Labs
16.6.1. Company Snapshot
16.6.2. Interview Transcript: Gaurav Patel, Chief Technical Officer
16.7. etectRx
16.7.1. Company Snapshot
16.7.2. Interview Transcript: Tina Valbh, Strategy and Business Development (Advisor)
16.8. PharmAdva
16.8.1. Company Snapshot
16.8.2. Interview Transcript: Jonathan Sacks, Chief Executive Officer and Chairman
16.9. Popit Technologies
16.9.1. Company Snapshot
16.9.2. Interview Transcript: Timo Heikkilä, Co-Founder and Chief Operating Officer
16.10. Wealth Taxi
16.10.1. Company Snapshot
16.10.2. Interview Transcript: Moore Greenberg, Founder
16.11 Small-sized Company
16.11.1 Interview Transcript: Anonymous

17. Appendix 1: Tabulated Data

18. Appendix 2: List of Companies and Organizations

List of Tables
Table 3.1 Medication Adherence: Methods of Measurement
Table 3.2 Traditional Interventions for Improving Medication Adherence
Table 4.1 Smart Drug Delivery Devices: Information on Developers
Table 4.2 Smart Drug Delivery Devices: Information on Key Device Specifications
Table 5.1 Smart Accessory Devices: Information on Developers
Table 5.2 Smart Accessory Devices: Information on Key Device Specifications
Table 5.3 Compliance Packaging Systems: Information on Developers
Table 5.4 Compliance Packaging Systems: Information on Key Specifications
Table 6.1 USFDA Centers for Drugs and Device Approval
Table 6.2 USFDA: Review Timelines
Table 6.3 Regulatory Bodies in EU5 Countries
Table 6.4 SFDA: Regulatory Review Timeline
Table 7.1 Adherium: List of Medications Used with Hailie™ Sensors
Table 7.2 Adherium: Recent Developments and Future Outlook
Table 7.3 BIOCORP: Recent Developments and Future Outlook
Table 7.4 nGageIT Digital Health: Recent Developments and Future Outlook
Table 7.5 Proteus Digital Health: Recent Developments and Future Outlook
Table 7.6 SOOIL Development: Recent Developments and Future Outlook
Table 7.7 Ypsomed: Specifications of mylife™ YpsoPump®:
Table 7.8 Ypsomed: Recent Developments and Future Outlook
Table 8.1 AARDEX Group: Recent Developments and Future Outlook
Table 8.2 Information Mediary: Specifications of Med-ic® Electronic Compliance Monitor®
Table 8.3 Information Mediary: Specifications of eCap™ Electronic Compliance Monitor®
Table 8.4 Information Mediary: Specifications of Med-ic® Coolblue Syringe Pack
Table 8.5 Information Mediary: Specifications of CertiScan® Reader and Software
Table 8.6 Information Mediary: Areas of Application of Med-ic® Smart Label and eCap™
Table 8.7 Information Mediary: Recent Developments and Future Outlook
Table 8.8 MedMinder Systems: Recent Developments and Future Outlook
Table 8.9 Philips: Specifications of spencer®
Table 8.10 Philips: Key Features and Advantages of Philips Automated Medication Dispensing Services
Table 8.11 Philips: Recent Developments and Future Outlook
Table 8.12 Vaica: Specifications of SimpleMed+
Table 8.13 Vaica: Specifications of SimpleMedRX
Table 8.14 Vaica: Specifications of Capsuled™
Table 8.15 Vaica: Specifications of SimpleMed Suit
Table 8.16 Vaica: Recent Developments and Future Outlook
Table 11.1 Drug Adherence Enhancement Market: Funding and Investments, January 2001-August 2018
Table 11.2 Funding and Investment Analysis: Summary of Investments
Table 12.1 Drug Adherence Enhancement: Partnerships and Collaborations, 2010-2018
Table 13.1 Medication Adherence: List of Mobile Applications
Table 13.2 Medication Adherence with Mobile Applications: List of Publications
Table 13.3 Medication Adherence with Mobile Applications: List of Clinical Trials
Table 13.4 Medication Adherence with Mobile Applications: Primary and Secondary Endpoint(s), and Study Outcomes of Clinical Trials
Table 16.1 AceAge: Key Highlights
Table 16.2 AdhereTech: Key Highlights
Table 16.3 Amiko Digital Health: Key Highlights
Table 16.4 Cognita Labs: Key Highlights
Table 16.5 etectRx: Key Highlights
Table 16.6 PharmAdva: Key Highlights
Table 16.7 Popit Technologies: Key Highlights
Table 16.8 Wealth Taxi: Key Highlights
Table 17.1 Smart Drug Delivery Devices: Distribution of Developers by Year of Establishment
Table 17.2 Smart Drug Delivery Devices: Distribution of Developers by Geographical Location (Region-wise)
Table 17.3 Smart Drug Delivery Devices: Distribution of Developers by Geographical Location (Country-wise)
Table 17.4 Smart Drug Delivery Devices: Distribution of Developers by Size (Employee Count)
Table 17.5 Smart Drug Delivery Devices: Distribution by Type of Device
Table 17.6 Smart Drug Delivery Devices: Distribution by Mode of Drug Delivery
Table 17.7 Smart Drug Delivery Devices: Distribution by Key Specifications
Table 17.8 Smart Drug Delivery Devices: Distribution by Availability of Audio / Visual Reminders
Table 17.9 Smart Drug Delivery Devices: Distribution by Availability of Connectivity (USB, Bluetooth or Cellular)
Table 17.10 Smart Drug Delivery Devices: Distribution by Availability of Companion Mobile Application
Table 17.11 Smart Drug Delivery Devices: Distribution by Availability of Companion Mobile Application and Companion Web Portal
Table 17.12 Smart Drug Delivery Devices: Distribution by Availability of Companion Mobile Application and Data Storage / Cloud Platform
Table 17.13 Smart Drug Delivery Devices: Distribution by Battery Backup / Rechargeable Battery
Table 17.14 Smart Drug Delivery Devices: Key Players
Table 17.15 Smart Inhalers: Distribution of Developers by Year of Establishment
Table 17.16 Smart Inhalers: Distribution of Developers by Geographical Location
Table 17.17 Smart Inhalers: Distribution of Developers by Size (Employee Count)
Table 17.18 Smart Inhalers: Distribution by Key Device Specifications
Table 17.19 Smart Injectors: Distribution of Developers by Year of Establishment
Table 17.20 Smart Injectors: Distribution of Developers by Geographical Location
Table 17.21 Smart Injectors: Distribution of Developers by Size (Employee Count)
Table 17.22 Smart Injectors: Distribution by Key Device Specifications
Table 17.23 Smart Wearable Injectors: Distribution of Developers by Year of Establishment
Table 17.24 Smart Wearable Injectors: Distribution of Developers by Geographical Location
Table 17.25 Smart Wearable Injectors: Distribution of Developers by Size (Employee Count)
Table 17.26 Smart Wearable Injectors: Distribution by Key Device Specifications
Table 17.27 Smart Pills / Other Smart Devices: Distribution of Developers by Year of Establishment
Table 17.28 Smart Pills / Other Smart Devices: Distribution of Developers by Geographical Location
Table 17.29 Smart Pills / Other Smart Devices: Distribution of Developers by Size (Employee Count)
Table 17.30 Smart Pills / Other Smart Devices: Distribution by Key Device Specifications
Table 17.31 Smart Accessory Devices: Distribution of Developers by Year of Establishment
Table 17.32 Smart Accessory Devices: Distribution of Developers by Geographical Location (Region-wise)
Table 17.33 Smart Accessory Devices: Distribution of Developers by Geographical Location (Country-wise)
Table 17.34 Smart Accessory Devices: Distribution of Developers by Size (Employee Count)
Table 17.35 Smart Accessory Devices: Distribution by Type of Device
Table 17.36 Smart Accessory Devices: Distribution by Key Specifications
Table 17.37 Smart Accessory Devices: Distribution by Availability of Audio / Visual Reminders
Table 17.38 Smart Accessory Devices: Distribution by Availability of Connectivity (USB, Bluetooth, Wi-Fi or Cellular)
Table 17.39 Smart Accessory Devices: Distribution by Availability of Companion Mobile Application
Table 17.40 Smart Accessory Devices: Distribution by Availability of Companion Web Portal
Table 17.41 Smart Accessory Devices: Distribution by Availability of Data Storage / Cloud Platform
Table 17.42 Smart Accessory Devices: Distribution by Availability of Battery Backup / Rechargeable
Table 17.43 Smart Accessory Devices: Key Players
Table 17.44 Smart Medication Dispensers: Distribution of Developers by Year of Establishment
Table 17.45 Smart Medication Dispensers: Distribution of Developers by Geographical Location
Table 17.46 Smart Medication Dispensers: Distribution of Developers by Size (Employee Count)
Table 17.47 Smart Medication Dispensers: Distribution by Key Device Specifications
Table 17.48 Smart Pill Bottles / Caps: Distribution of Developers by Year of Establishment
Table 17.49 Smart Pill Bottles / Caps: Distribution of Developers by Geographical Location
Table 17.50 Smart Pill Bottles / Caps: Distribution of Developers by Size (Employee Count)
Table 17.51 Smart Pill Bottles / Caps: Distribution by Key Device Specifications
Table 17.52 Smart Pill Boxes: Distribution of Developers by Year of Establishment
Table 17.53 Smart Pill Boxes: Distribution of Developers by Geographical Location
Table 17.54 Smart Pill Boxes: Distribution of Developers by Size (Employee Count)
Table 17.55 Smart Pill Boxes: Distribution by Key Device Specifications
Table 17.56 Smart Blister Packs: Distribution of Developers by Year of Establishment
Table 17.57 Smart Blister Packs: Distribution of Developers by Geographical Location
Table 17.58 Smart Blister Packs: Distribution of Developers by Size (Employee Count)
Table 17.59 Smart Blister Packs: Distribution by Key Device Specifications
Table 17.60 Other Smart Devices: Distribution of Developers by Year of Establishment
Table 17.61 Other Smart Devices: Distribution of Developers by Geographical Location
Table 17.62 Other Smart Devices: Distribution of Developers by Size (Employee Count)
Table 17.63 Other Smart Devices: Distribution by Key Device Specifications
Table 17.64 Compliance Packaging Systems: Distribution of Developers by Geographical Location
Table 17.65 Compliance Packaging Systems: Distribution of Developers by Size (Employee Count)
Table 17.66 Compliance Packaging Systems: Distribution by Type of Packaging System
Table 17.67 Compliance Packaging Systems: Distribution by Number of Doses per Pack
Table 17.68 Compliance Packaging Systems: Distribution by Availability of Other Features  
Table 17.69 Adherium: Annual Revenues, FY1516-H1 FY1718 (USD Million)
Table 17.70 BIOCORP: Annual Revenues, 2014-2017 (EUR Million)
Table 17.71 Ypsomed: Annual Revenues, FY1314 - FY1718 (CHF Million)
Table 17.72 Ypsomed: Sales by Business Divisions, FY1718 (CHF Million)
Table 17.73 Philips: Annual Revenues, 2013- H1 2018 (EUR Billion)
Table 17.74 Philips: Revenues by Business Segments, H1 2018 (EUR Billion)
Table 17.75 Overall Product Competitiveness Analysis
Table 17.76 Overall Product Competitiveness Analysis: Distribution of Different Types of Products by Scores
Table 17.77 Funding and Investment Analysis: Cumulative Number of Instances, January 2001 - August 2018
Table 17.78 Funding and Investment Analysis: Cumulative Amount Invested, January 2001-August 2018 (USD Million)
Table 17.79 Funding and Investment Analysis: Distribution by Type of Funding, January 2001 - August 2018
Table 17.80 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding, January 2001 - August 2018 (USD Million)
Table 17.81 Funding and Investment Analysis: Summary of Investments, January 2001-August 2018 (USD Million)
Table 17.82 Funding and Investment Analysis: Distribution of Number of Funding Instances by Year of Investment and Major Device Categories, January 2001- August 2018
Table 17.83 Funding and Investment Analysis: Distribution of Number of Funding Instances by Type of Funding and Major Device Categories, January 2001-August 2018
Table 17.84 Funding and Investment Analysis: Distribution of Amount Invested by Year of Investment and Major Device Categories, January 2001- August 2018
Table 17.85 Funding and Investment Analysis: Most Active Players in terms of Number of Instances, January 2001-August 2018
Table 17.86 Funding and Investment Analysis: Most Active Players in Terms of Amount Raised (USD Million), January 2001-August 2018
Table 17.87 Funding and Investment Analysis: Most Active Investors
Table 17.88 Funding and Investment Summary
Table 17.89 Partnerships and Collaborations: Distribution by Year, 2010-2018
Table 17.90 Partnerships and Collaborations: Distribution by Type of Partnership
Table 17.91 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Table 17.92 Partnerships and Collaborations: Most Active Players
Table 17.93 Partnerships and Collaborations: Distribution by Type and Year of Partnership
Table 17.94 Partnerships and Collaborations: Distribution by Type and Geographical Presence of Companies
Table 17.95 Partnerships and Collaborations: Regional Distribution
Table 17.96 Medication Adherence Clinical Trial Publications for Software Applications: Distribution by Therapeutic Areas
Table 17.97 Global Drug Adherence Enhancement Market, Conservative, Base and Optimistic Scenarioss, Scenarios2018-2030 (USD Billion)
Table 17.98 Drug Adherence Enhancement Market for Smart Drug Delivery Devices, Conservative, Base and Optimistic Scenarios, Scenarios2018-2030 (USD Billion)
Table 17.99 Drug Adherence Enhancement Market for Smart Accessory Devices, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.100 Drug Adherence Enhancement Market for Other Type of Devices, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.101 Global Drug Adherence Enhancement Market, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.102 Digital Drug Adherence Enhancement Market for Smart Drug Delivery Devices, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.103 Drug Adherence Enhancement Market for Smart Accessory Devices, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.104 Drug Adherence Enhancement Market for Other Type of Devices, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.105 Drug Adherence Enhancement Market in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.106 Drug Adherence Enhancement Market in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.107 Drug Adherence Enhancement Market in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.108 Drug Adherence Enhancement Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.109 Drug Adherence Enhancement Market for Smart Inhalers, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.110 Drug Adherence Enhancement Market for Smart Inhalers in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.111 Drug Adherence Enhancement Market for Smart Inhalers in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.112 Drug Adherence Enhancement Market for Smart Inhalers in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.113 Drug Adherence Enhancement Market for Smart Inhalers in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.114 Drug Adherence Enhancement Market for Smart Injectors, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.115 Drug Adherence Enhancement Market for Smart Injectors in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.116 Drug Adherence Enhancement Market for Smart Injectors in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.117 Drug Adherence Enhancement Market for Smart Injectors in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.118 Drug Adherence Enhancement Market for Smart Injectors in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.119 Drug Adherence Enhancement Market for Smart Wearable Injectors, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.120 Drug Adherence Enhancement Market for Smart Wearable Injectors in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.121 Digital Drug Adherence Enhancement Market for Smart Wearable Injectors in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.122 Drug Adherence Enhancement Market for Smart Wearable Injectors in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.123 Drug Adherence Enhancement Market for Smart Wearable Injectors in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.124 Drug Adherence Enhancement Market for Smart Pills, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.125 Drug Adherence Enhancement Market for Smart Pills in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.126 Drug Adherence Enhancement Market for Smart Pills in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.127 Drug Adherence Enhancement Market for Smart Pills in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.128 Drug Adherence Enhancement Market for Smart Pills in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.129 Drug Adherence Enhancement Market for Smart Medication Dispensers, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.130 Drug Adherence Enhancement Market for Smart Medication Dispensers in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.131 Drug Adherence Enhancement Market for Smart Medication Dispensers in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.132 Drug Adherence Enhancement Market for Smart Medication Dispensers in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.133 Drug Adherence Enhancement Market for Smart Medication Dispensers in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.134 Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.135 Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in North America, Conservative, Base and Optimistic Scenarios, 2018-2030
(USD Billion)
Table 17.136 Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD
Billion)
Table 17.137 Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030
(USD Billion)
Table 17.138 Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-
2030 (USD Billion)
Table 17.139 Drug Adherence Enhancement Market for Smart Blister Packs, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.140 Drug Adherence Enhancement Market for Smart Blister Packs in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.141 Drug Adherence Enhancement Market for Smart Blister Packs in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.142 Drug Adherence Enhancement Market for Smart Blister Packs in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.143 Drug Adherence Enhancement Market for Smart Blister Packs in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.144 Drug Adherence Enhancement Market for Other Type of Products, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.145 Drug Adherence Enhancement Market for Other Type of Products in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.146 Drug Adherence Enhancement Market for Other Type of Products in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.147 Drug Adherence Enhancement Market for Other Type of Products in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.148 Drug Adherence Enhancement Market for Other Type of Products in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.149 Drug Adherence Enhancement Market for Smart Inhalers, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.150 Drug Adherence Enhancement Market for Smart Inhalers in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.151 Drug Adherence Enhancement Market for Smart Inhalers in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.152 Drug Adherence Enhancement Market for Smart Inhalers in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.153 Drug Adherence Enhancement Market for Smart Inhalers in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.154 Drug Adherence Enhancement Market for Smart Injectors, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.155 Drug Adherence Enhancement Market for Smart Injectors in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.156 Drug Adherence Enhancement Market for Smart Injectors in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.157 Drug Adherence Enhancement Market for Smart Injectors in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.158 Drug Adherence Enhancement Market for Smart Injectors in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.159 Drug Adherence Enhancement Market for Smart Wearable Injectors, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.160 Drug Adherence Enhancement Market for Smart Wearable Injectors in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.161 Digital Drug Adherence Enhancement Market for Smart Wearable Injectors in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.162 Drug Adherence Enhancement Market for Smart Wearable Injectors in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.163 Drug Adherence Enhancement Market for Smart Wearable Injectors in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.164 Drug Adherence Enhancement Market for Smart Pills, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.165 Drug Adherence Enhancement Market for Smart Pills in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.166 Drug Adherence Enhancement Market for Smart Pills in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.167 Drug Adherence Enhancement Market for Smart Pills in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.168 Drug Adherence Enhancement Market for Smart Pills in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.169 Drug Adherence Enhancement Market for Smart Medication Dispensers, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.170 Drug Adherence Enhancement Market for Smart Medication Dispensers in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.171 Drug Adherence Enhancement Market for Smart Medication Dispensers in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.172 Drug Adherence Enhancement Market for Smart Medication Dispensers in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.173 Drug Adherence Enhancement Market for Smart Medication Dispensers in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.174 Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.175 Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.176 Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.177 Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.178 Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.179 Drug Adherence Enhancement Market for Smart Blister Packs, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.180 Drug Adherence Enhancement Market for Smart Blister Packs in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.181 Drug Adherence Enhancement Market for Smart Blister Packs in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.182 Drug Adherence Enhancement Market for Smart Blister Packs in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.183 Drug Adherence Enhancement Market for Smart Blister Packs in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.184 Drug Adherence Enhancement Market for Other Type of Products, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.185 Drug Adherence Enhancement Market for Other Type of Products in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.186 Drug Adherence Enhancement Market for Other Type of Products in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.187 Drug Adherence Enhancement Market for Other Type of Products in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.188 Drug Adherence Enhancement Market for Other Type of Products in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.189 Drug Adherence Enhancement Market for Metabolic Disorders, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.190 Drug Adherence Enhancement Market for Metabolic Disorders in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.191 Drug Adherence Enhancement Market for Metabolic Disorders in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.192 Drug Adherence Enhancement Market for Metabolic Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.193 Drug Adherence Enhancement Market for Metabolic Disorders in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.194 Drug Adherence Enhancement Market for Cardiovascular Disorders, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.195 Drug Adherence Enhancement Market for Cardiovascular Disorders in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.196 Drug Adherence Enhancement Market for Cardiovascular Disorders in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.197 Drug Adherence Enhancement Market for Cardiovascular Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.198 Drug Adherence Enhancement Market for Cardiovascular Disorders in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.199 Drug Adherence Enhancement Market for Respiratory Disorders, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.200 Drug Adherence Enhancement Market for Respiratory Disorders in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.201 Drug Adherence Enhancement Market for Respiratory Disorders in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.202 Drug Adherence Enhancement Market for Respiratory Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.203 Drug Adherence Enhancement Market for Respiratory Disorders in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.204 Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.205 Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.206 Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.207 Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in Asia-Pacific, Conservative, Base and Optimistic
Scenarios, 2018-2030 (USD Billion)
Table 17.208 Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.209 Drug Adherence Enhancement Market for Other Disorders, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.209 Drug Adherence Enhancement Market for Other Disorders in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.210 Drug Adherence Enhancement Market for Other Disorders in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.211 Drug Adherence Enhancement Market for Other Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.212 Drug Adherence Enhancement Market for Other Disorders in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.213 Drug Adherence Enhancement Market for Metabolic Disorders, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.214 Drug Adherence Enhancement Market for Metabolic Disorders in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.215 Drug Adherence Enhancement Market for Metabolic Disorders in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.216 Drug Adherence Enhancement Market for Metabolic Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.217 Drug Adherence Enhancement Market for Metabolic Disorders in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.218 Drug Adherence Enhancement Market for Cardiovascular Disorders, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.219 Drug Adherence Enhancement Market for Cardiovascular Disorders in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.220 Drug Adherence Enhancement Market for Cardiovascular Disorders in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.221 Drug Adherence Enhancement Market for Cardiovascular Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.222 Drug Adherence Enhancement Market for Cardiovascular Disorders in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.223 Drug Adherence Enhancement Market for Respiratory Disorders, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.224 Drug Adherence Enhancement Market for Respiratory Disorders in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.225 Drug Adherence Enhancement Market for Respiratory Disorders in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.226 Drug Adherence Enhancement Market for Respiratory Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.227 Drug Adherence Enhancement Market for Respiratory Disorders in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.228 Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.229 Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in North America, Conservative, Base and Optimistic
Scenarios, 2018-2030 (Units, Million)
Table 17.230 Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.231 Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.232 Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.233 Drug Adherence Enhancement Market for Other Disorders, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.234 Drug Adherence Enhancement Market for Other Disorders in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.235 Drug Adherence Enhancement Market for Other Disorders in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.236 Drug Adherence Enhancement Market for Other Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.237 Drug Adherence Enhancement Market for Other Disorders in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.238 Drug Adherence Enhancement Market for Products Intended for Oral Medications, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.239 Drug Adherence Enhancement Market for Products Intended for Oral Medications in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.240 Drug Adherence Enhancement Market for Products Intended for Oral Medications in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.241 Drug Adherence Enhancement Market for Products Intended for Oral Medications in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.242 Drug Adherence Enhancement Market for Products Intended for Oral Medications in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.243 Drug Adherence Enhancement Market for Products Intended for Injectables, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.244 Drug Adherence Enhancement Market for Products Intended for Injectables in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.245 Drug Adherence Enhancement Market for Products Intended for Injectables in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.246 Drug Adherence Enhancement Market for Products Intended for Injectables in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.247 Drug Adherence Enhancement Market for Products Intended for Injectables in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.248 Drug Adherence Enhancement Market for Products Intended for Inhalable Medications, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.249 Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.250 Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.251 Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.252 Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.253 Drug Adherence Enhancement Market for Products Intended for Other Medications, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.254 Drug Adherence Enhancement Market for Products Intended for Other Medications in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.255 Drug Adherence Enhancement Market for Products Intended for Other Medications in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.256 Drug Adherence Enhancement Market for Products Intended for Other Medications in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.257 Drug Adherence Enhancement Market for Products Intended for Other Medications in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.258 Drug Adherence Enhancement Market for Products Intended for Oral Medications, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.259 Drug Adherence Enhancement Market for Products Intended for Oral Medications in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.260 Drug Adherence Enhancement Market for Products Intended for Oral Medications in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.261 Drug Adherence Enhancement Market for Products Intended for Oral Medications in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.262 Drug Adherence Enhancement Market for Products Intended for Oral Medications in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.263 Drug Adherence Enhancement Market for Products Intended for Injectables, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.264 Drug Adherence Enhancement Market for Products Intended for Injectables in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.265 Drug Adherence Enhancement Market for Products Intended for Injectables in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.266 Drug Adherence Enhancement Market for Products Intended for Injectables in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.267 Drug Adherence Enhancement Market for Products Intended for Injectables in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.268 Drug Adherence Enhancement Market for Products Intended for Inhalable Medications, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.269 Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in North America, Conservative, Base and Optimistic Scenarios, 2018-2030
(Units, Million)
Table 17.270 Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.271 Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.272 Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.273 Drug Adherence Enhancement Market for Products Intended for Other Medications, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.274 Drug Adherence Enhancement Market for Products Intended for Other Medications in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.275 Drug Adherence Enhancement Market for Products Intended for Other Medications in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.276 Drug Adherence Enhancement Market for Products Intended for Other Medications in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.277 Drug Adherence Enhancement Market for Products Intended for Other Medications in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)

List of Figures
Figure 3.1 Types of Medication Non-Adherence
Figure 3.2 Factors Contributing to Non-Adherence
Figure 3.3 Framework of IoT Assisted Adherence Platform
Figure 4.1 Smart Drug Delivery Devices: Distribution of Developers by Year of Establishment
Figure 4.2 Smart Drug Delivery Devices: Distribution of Developers by Geographical Location (Region-wise)
Figure 4.3 Smart Drug Delivery Devices: Distribution of Developers by Geographical Location (Country-wise)
Figure 4.4 Smart Drug Delivery Devices: Distribution of Developers by Size (Employee Count)
Figure 4.5 Smart Drug Delivery Devices: Distribution by Type of Device
Figure 4.6 Smart Drug Delivery Devices: Distribution by Mode of Drug Delivery
Figure 4.7 Smart Drug Delivery Devices: Distribution by Key Specifications
Figure 4.8 Smart Drug Delivery Devices: Distribution by Availability of Audio / Visual Reminders
Figure 4.9 Smart Drug Delivery Devices: Distribution by Availability of Connectivity (USB, Bluetooth, or Cellular)
Figure 4.10 Smart Drug Delivery Devices: Distribution by Availability of Companion Mobile Application
Figure 4.11 Smart Drug Delivery Devices: Distribution by Availability of Companion Web Portal
Figure 4.12 Smart Drug Delivery Devices: Distribution by Availability of Data Storage / Cloud Platform
Figure 4.13 Smart Drug Delivery Devices: Distribution by Battery Backup / Rechargeable Battery
Figure 4.14 Smart Drug Delivery Devices: Key Players
Figure 4.15 Smart Inhalers: Distribution of Developers by Year of Establishment
Figure 4.16 Smart Inhalers: Distribution of Developers by Geographical Location
Figure 4.17 Smart Inhalers: Distribution of Developers by Size (Employee Count)
Figure 4.18 Smart Inhalers: Distribution by Key Device Specifications
Figure 4.19 Smart Injectors: Distribution of Developers by Year of Establishment
Figure 4.20 Smart Injectors: Distribution of Developers by Geographical Location
Figure 4.21 Smart Injectors: Distribution of Developers by Size (Employee Count)
Figure 4.22 Smart Injectors: Distribution by Key Device Specifications
Figure 4.23 Smart Wearable Injectors: Distribution of Developers by Year of Establishment
Figure 4.24 Smart Wearable Injectors: Distribution of Developers by Geographical Location
Figure 4.25 Smart Wearable Injectors: Distribution of Developers by Size (Employee Count)
Figure 4.26 Smart Wearable Injectors: Distribution by Key Device Specifications
Figure 4.27 Smart Pills / Other Smart Devices: Distribution of Developers by Year of Establishment
Figure 4.28 Smart Pills / Other Smart Devices: Distribution of Developers by Geographical Location
Figure 4.29 Smart Pills / Other Smart Devices: Distribution of Developers by Size (Employee Count)
Figure 4.30 Smart Pills / Other Smart Devices: Distribution by Key Device Specifications
Figure 5.1 Smart Accessory Devices: Distribution of Developers by Year of Establishment
Figure 5.2 Smart Accessory Devices: Distribution of Developers by Geographical Location (Region-wise)
Figure 5.3 Smart Accessory Devices: Distribution of Developers by Geographical Location (Country-wise)
Figure 5.4 Smart Accessory Devices: Distribution of Developers by Size (Employee Count)
Figure 5.5 Smart Accessory Devices: Distribution by Type of Device
Figure 5.6 Smart Accessory Devices: Distribution by Key Specifications
Figure 5.7 Smart Accessory Devices: Distribution by Availability of Audio / Visual Reminders
Figure 5.8 Smart Accessory Devices: Distribution by Availability of Connectivity (USB, Bluetooth, Wi-Fi, or Cellular)
Figure 5.9 Smart Accessory Devices: Distribution by Availability of Companion Mobile Application
Figure 5.10 Smart Accessory Devices: Distribution by Availability of Companion Web Portal
Figure 5.11 Smart Accessory Devices: Distribution by Availability of Data Storage / Cloud Platform
Figure 5.12 Smart Accessory Devices: Distribution by Availability of Battery Backup / Rechargeable
Figure 5.13 Smart Accessory Devices: Key Players
Figure 5.14 Smart Medication Dispensers: Distribution of Developers by Year of Establishment
Figure 5.15 Smart Medication Dispensers: Distribution of Developers by Geographical Location
Figure 5.16 Smart Medication Dispensers: Distribution of Developers by Size (Employee Count)
Figure 5.17 Smart Medication Dispensers: Distribution by Key Device Specifications
Figure 5.18 Smart Pill Bottles / Caps: Distribution of Developers by Year of Establishment
Figure 5.19 Smart Pill Bottles / Caps: Distribution of Developers by Geographical Location
Figure 5.20 Smart Pill Bottles / Caps: Distribution of Developers by Size (Employee Count)
Figure 5.21 Smart Pill Bottles / Caps: Distribution by Key Device Specifications
Figure 5.22 Smart Pill Boxes: Distribution of Developers by Year of Establishment
Figure 5.23 Smart Pill Boxes: Distribution of Developers by Geographical Location
Figure 5.24 Smart Pill Boxes: Distribution of Developers by Size (Employee Count)
Figure 5.25 Smart Pill Boxes: Distribution by Key Device Specifications
Figure 5.26 Smart Blister Packs: Distribution of Developers by Year of Establishment
Figure 5.27 Smart Blister Packs: Distribution of Developers by Geographical Location
Figure 5.28 Smart Blister Packs: Distribution of Developers by Size (Employee Count)
Figure 5.29 Smart Blister Packs: Distribution by Key Device Specifications
Figure 5.30 Other Smart Devices: Distribution of Developers by Year of Establishment
Figure 5.31 Other Smart Devices: Distribution of Developers by Geographical Location
Figure 5.32 Other Smart Devices: Distribution of Developers by Size (Employee Count)
Figure 5.33 Other Smart Devices: Distribution by Key Device Specifications
Figure 5.34 Compliance Packaging Systems: Distribution of Developers by Geographical Location
Figure 5.35 Compliance Packaging Systems: Distribution of Developers by Size (Employee Count)
Figure 5.36 Compliance Packaging Systems: Distribution by Type of Packaging System
Figure 5.37 Compliance Packaging Systems: Distribution by Number of Doses per Pack
Figure 5.38 Compliance Packaging Systems: Distribution by Availability of Other Features
Figure 6.1 Global Regulations Related to Smart Inhalers, Smart Injectors and Smart Wearable Injectors
Figure 6.2 USFDA: Approval Pathway for Combination Products
Figure 6.3 Health Canada: Approval Pathway for Combination Products
Figure 6.4 CFDA: Approval Pathway of Combination Products
Figure 7.1 Adherium: Annual Revenues, FY 2015-H1 FY 2018 (USD Million)
Figure 7.2 Adherium: Working Mechanism of Hailie™
Figure 7.3 BIOCORP: Annual Revenues, 2014-2017 (EUR Million)
Figure 7.4 nGageIT Digital Health: Data Points Captured by Nanoparticle Sensor
Figure 7.5 nGageIT Digital Health: Key Features of nGageIT Injectable Sensor Technologies
Figure 7.6 Proteus Digital Health: Major Components of Proteus Discover
Figure 7.7 Ypsomed: Annual Revenues, FY2013 - FY2017 (CHF Million)
Figure 7.8 Ypsomed: Sales by Business Divisions, FY2017 (CHF Million)
Figure 7.9. Ypsomed: Features of YpsoMate® SmartPilot
Figure 7.10. Ypsomed: Components of mylife Ypsopump
Figure 8.1 MedMinder Systems: Key Features of Pill Dispensers
Figure 8.2 MedMinder Systems: Key Differences of Pill Dispensers
Figure 8.3 Philips: Annual Revenues, 2013- H1 2018 (EUR Billion)
Figure 8.4 Philips: Revenues by Business Segments, H1 2018 (EUR Billion)
Figure 8.5 Philips: Key Features of spencer®
Figure 8.6 Tinylogics: Key Features of Memo Box
Figure 8.7 Vaica: Complete Range of Solutions
Figure 8.8 Vaica: Study Results
Figure 9.1 Diabetes: Global Prevalence
Figure 9.2 Diabetes: Evolution of Drug Delivery / Connected Devices
Figure 9.3 Impact of Drug Delivery / Connected Devices in Improving Drug Adherence in Diabetic Patients: Highlights on Twitter
Figure 9.4 Asthma: Global Prevalence
Figure 9.5 Asthma: Evolution of Drug Delivery / Connected Devices
Figure 9.6 Smart Inhalers / Connected Devices: Potential Applications
Figure 9.10 Impact of Drug Delivery / Connected Devices in Improving Drug Adherence in Asthma Patients: Highlights on Twitter
Figure 9.11 Rheumatoid Arthritis: Global Prevalence
Figure 9.12 Rheumatoid Arthritis: Evolution of Drug Delivery / Connected Devices
Figure 9.13 Impact of Drug Delivery / Connected Devices in Improving Drug Adherence in Rheumatoid Arthritis Patients: Highlights on Twitter
Figure 10.1 Overall Product Competitiveness Analysis
Figure 10.2 Overall Product Competitiveness Analysis: Distribution of Different Types of Products by Scores
Figure 10.3 Product Competitiveness Analysis: Smart Medication Dispensers
Figure 10.4 Product Competitiveness Analysis: Smart Pill Packaging Systems
Figure 10.5 Product Competitiveness Analysis: Smart Inhalers
Figure 10.6 Product Competitiveness Analysis: Smart Injectors
Figure 10.7 Product Competitiveness Analysis: Smart Wearable Injectors
Figure 11.1 Funding and Investment Analysis: Cumulative Number of Instances, January 2001-August 2018
Figure 11.2 Funding and Investment Analysis: Cumulative Amount Invested, January 2001-August 2018 (USD Million)
Figure 11.3 Funding and Investment Analysis: Distribution by Type of Funding, January 2001-August 2018
Figure 11.4 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding, January 2001-August 2018 (USD Million)
Figure 11.5 Funding and Investment Analysis: Summary of Investments, January 2001-August 2018 (USD Million)
Figure 11.6 Funding and Investment Analysis: Distribution of Number of Funding Instances by Year of Investment and Major Device Categories, January 2001-August 2018
Figure 11.7 Funding and Investment Analysis: Distribution of Number of Funding Instances by Type of Funding and Major Device Categories, January 2001-August 2018
Figure 11.8 Funding and Investment Analysis: Distribution of Amount Invested by Year of Investment and Major Device Categories, January 2001-August 2018
Figure 11.9 Funding and Investment Analysis: Most Active Players in terms of Number of Instances, January 2001-August 2018
Figure 11.10 Funding and Investment Analysis: Most Active Players in terms of Amount Raised (USD Million), January 2001-August 2018
Figure 11.12 Funding and Investment Analysis: Most Active Investors
Figure 11.13 Funding and Investment Summary
Figure 12.1 Partnerships and Collaborations: Distribution by Year, 2010-2018
Figure 12.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 12.3 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Figure 12.4 Partnerships and Collaborations: Most Active Players
Figure 12.5 Partnerships and Collaborations: Distribution by Type and Year of Partnership
Figure 12.6 Partnerships and Collaborations: Distribution by Type of Partnership and Geographical Presence of Companies
Figure 12.7 Partnerships and Collaborations: Regional Distribution
Figure 13.1 Clinical Trial Publications for Improving Medication Adherence through Software Applications: Distribution by Therapeutic Areas
Figure 14.1 Global Drug Adherence Enhancement Market, 2018-2030 (USD Billion)
Figure 14.2 Drug Adherence Enhancement Market for Smart Drug Delivery Devices, 2018-2030 (USD Billion)
Figure 14.3 Drug Adherence Enhancement Market for Smart Accessory Devices, 2018-2030 (USD Billion)
Figure 14.4 Drug Adherence Enhancement Market for Other Type of Devices, 2018-2030 (USD Billion)
Figure 14.5 Global Drug Adherence Enhancement Market, 2018-2030 (Units, Million)
Figure 14.6 Drug Adherence Enhancement Market for Smart Drug Delivery Devices, 2018-2030 (Units, Million)
Figure 14.7 Drug Adherence Enhancement Market for Smart Accessory Devices, 2018-2030 (Units, Million)
Figure 14.8 Drug Adherence Enhancement Market for Other Type of Devices, 2018-2030 (Units, Million)
Figure 14.9 Drug Adherence Enhancement Market in North America, 2018-2030 (USD Billion)
Figure 14.10 Drug Adherence Enhancement Market in Europe, 2018-2030 (USD Billion)
Figure 14.11 Drug Adherence Enhancement Market in Asia-Pacific, 2018-2030 (USD Billion)
Figure 14.12 Drug Adherence Enhancement Market in Rest of the World, 2018-2030 (USD Billion)
Figure 14.13 Drug Adherence Enhancement Market for Smart Inhalers, 2018-2030 (USD Billion)
Figure 14.14 Drug Adherence Enhancement Market for Smart Inhalers in North America, 2018-2030 (USD Billion)
Figure 14.15 Drug Adherence Enhancement Market for Smart Inhalers in Europe, 2018-2030 (USD Billion)
Figure 14.16 Drug Adherence Enhancement Market for Smart Inhalers in Asia-Pacific, 2018-2030 (USD Billion)
Figure 14.17 Drug Adherence Enhancement Market for Smart Inhalers in Rest of the World, 2018-2030 (USD Billion)
Figure 14.18 Drug Adherence Enhancement Market for Smart Injectors, 2018-2030 (USD Billion)
Figure 14.19 Drug Adherence Enhancement Market for Smart Injectors in North America, 2018-2030 (USD Billion)
Figure 14.20 Drug Adherence Enhancement Market for Smart Injectors in Europe, 2018-2030 (USD Billion)
Figure 14.21 Drug Adherence Enhancement Market for Smart Injectors in Asia-Pacific, 2018-2030 (USD Billion)
Figure 14.22 Drug Adherence Enhancement Market for Smart Injectors in Rest of the World, 2018-2030 (USD Billion)
Figure 14.23 Drug Adherence Enhancement Market for Smart Wearable Injectors, 2018-2030 (USD Billion)
Figure 14.24 Drug Adherence Enhancement Market for Smart Wearable Injectors in North America, 2018-2030 (USD Billion)
Figure 14.25 Drug Adherence Enhancement Market for Smart Wearable Injectors in Europe, 2018-2030 (USD Billion)
Figure 14.26 Drug Adherence Enhancement Market for Smart Wearable Injectors in Asia-Pacific, 2018-2030 (USD Billion)
Figure 14.27 Drug Adherence Enhancement Market for Smart Wearable Injectors in Rest of the World, 2018-2030 (USD Billion)
Figure 14.28 Drug Adherence Enhancement Market for Smart Pills, 2018-2030 (USD Billion)
Figure 14.29 Drug Adherence Enhancement Market for Smart Pills in North America, 2018-2030 (USD Billion)
Figure 14.30 Drug Adherence Enhancement Market for Smart Pills in Europe, 2018-2030 (USD Billion)
Figure 14.31 Drug Adherence Enhancement Market for Smart Pills in Asia-Pacific, 2018-2030 (USD Billion)
Figure 14.32 Drug Adherence Enhancement Market for Smart Pills in Rest of the World, 2018-2030 (USD Billion)
Figure 14.33 Drug Adherence Enhancement Market for Smart Medication Dispensers, 2018-2030 (USD Billion)
Figure 14.34 Drug Adherence Enhancement Market for Smart Medication Dispensers in North America, 2018-2030 (USD Billion)
Figure 14.35 Drug Adherence Enhancement Market for Smart Medication Dispensers in Europe, 2018-2030 (USD Billion)
Figure 14.36 Drug Adherence Enhancement Market for Smart Medication Dispensers in Asia-Pacific, 2018-2030 (USD Billion)
Figure 14.37 Drug Adherence Enhancement Market for Smart Medication Dispensers in Rest of the World, 2018-2030 (USD Billion)
Figure 14.38 Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes, 2018-2030 (USD Billion)
Figure 14.39 Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in North America, 2018-2030 (USD Billion)
Figure 14.40 Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in Europe, 2018-2030 (USD Billion)
Figure 14.41 Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in Asia-Pacific, 2018-2030 (USD Billion)
Figure 14.42 Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in Rest of the World, 2018-2030 (USD Billion)
Figure 14.43 Drug Adherence Enhancement Market for Smart Blister Packs, 2018-2030 (USD Billion)
Figure 14.44 Drug Adherence Enhancement Market for Smart Blister Packs in North America, 2018-2030 (USD Billion)
Figure 14.45 Drug Adherence Enhancement Market for Smart Blister Packs in Europe, 2018-2030 (USD Billion)
Figure 14.46 Drug Adherence Enhancement Market for Smart Blister Packs in Asia-Pacific, 2018-2030 (USD Billion)
Figure 14.47 Drug Adherence Enhancement Market for Smart Blister Packs in Rest of the World, 2018-2030 (USD Billion)
Figure 14.48 Drug Adherence Enhancement Market for Other Type of Products, 2018-2030 (USD Billion)
Figure 14.49 Drug Adherence Enhancement Market for Other Type of Products in North America, 2018-2030 (USD Billion)
Figure 14.50 Drug Adherence Enhancement Market for Other Type of Products in Europe, 2018-2030 (USD Billion)
Figure 14.51 Drug Adherence Enhancement Market for Other Type of Products in Asia-Pacific, 2018-2030 (USD Billion)
Figure 14.52 Drug Adherence Enhancement Market for Other Type of Products in Rest of the World, 2018-2030 (USD Billion)
Figure 14.53 Drug Adherence Enhancement Market for Smart Inhalers, 2018-2030 (Units, Million)
Figure 14.54 Drug Adherence Enhancement Market for Smart Inhalers in North America, 2018-2030 (Units, Million)
Figure 14.55 Drug Adherence Enhancement Market for Smart Inhalers in Europe, 2018-2030 (Units, Million)
Figure 14.56 Drug Adherence Enhancement Market for Smart Inhalers in Asia-Pacific, 2018-2030 (Units, Million)
Figure 14.57 Drug Adherence Enhancement Market for Smart Inhalers in Rest of the World, 2018-2030 (Units, Million)
Figure 14.58 Drug Adherence Enhancement Market for Smart Injectors, 2018-2030 (Units, Million)
Figure 14.59 Drug Adherence Enhancement Market for Smart Injectors in North America, 2018-2030 (Units, Million)
Figure 14.60 Drug Adherence Enhancement Market for Smart Injectors in Europe, 2018-2030 (Units, Million)
Figure 14.61 Drug Adherence Enhancement Market for Smart Injectors in Asia-Pacific, 2018-2030 (Units, Million)
Figure 14.62 Drug Adherence Enhancement Market for Smart Injectors in Rest of the World, 2018-2030 (Units, Million)
Figure 14.63 Drug Adherence Enhancement Market for Smart Wearable Injectors, 2018-2030 (Units, Million)
Figure 14.64 Drug Adherence Enhancement Market for Smart Wearable Injectors in North America, 2018-2030 (Units, Million)
Figure 14.65 Drug Adherence Enhancement Market for Smart Wearable Injectors in Europe, 2018-2030 (Units, Million)
Figure 14.66 Drug Adherence Enhancement Market for Smart Wearable Injectors in Asia-Pacific, 2018-2030 (Units, Million)
Figure 14.67 Drug Adherence Enhancement Market for Smart Wearable Injectors in Rest of the World, 2018-2030 (Units, Million)
Figure 14.68 Drug Adherence Enhancement Market for Smart Pills, 2018-2030 (Units, Million)
Figure 14.69 Drug Adherence Enhancement Market for Smart Pills in North America, 2018-2030 (Units, Million)
Figure 14.70 Drug Adherence Enhancement Market for Smart Pills in Europe, 2018-2030 (Units, Million)
Figure 14.71 Drug Adherence Enhancement Market for Smart Pills in Asia-Pacific, 2018-2030 (Units, Million)
Figure 14.72 Drug Adherence Enhancement Market for Smart Pills in Rest of the World, 2018-2030 (Units, Million)
Figure 14.73 Drug Adherence Enhancement Market for Smart Medication Dispensers, 2018-2030 (Units, Million)
Figure 14.74 Drug Adherence Enhancement Market for Smart Medication Dispensers in North America, 2018-2030 (Units, Million)
Figure 14.75 Drug Adherence Enhancement Market for Smart Medication Dispensers in Europe, 2018-2030 (Units, Million)
Figure 14.76 Drug Adherence Enhancement Market for Smart Medication Dispensers in Asia-Pacific, 2018-2030 (Units, Million)
Figure 14.77 Drug Adherence Enhancement Market for Smart Medication Dispensers in Rest of the World, 2018-2030 (Units, Million)
Figure 14.78 Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes, 2018-2030 (Units, Million)
Figure 14.79 Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in North America, 2018-2030 (Units, Million)
Figure 14.80 Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in Europe, 2018-2030 (Units, Million)
Figure 14.81 Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in Asia-Pacific, 2018-2030 (Units, Million)
Figure 14.82 Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in Rest of the World, 2018-2030 (Units, Million)
Figure 14.83 Drug Adherence Enhancement Market for Smart Blister Packs, 2018-2030 (Units, Million)
Figure 14.84 Drug Adherence Enhancement Market for Smart Blister Packs in North America, 2018-2030 (Units, Million)
Figure 14.85 Drug Adherence Enhancement Market for Smart Blister Packs in Europe, 2018-2030 (Units, Million)
Figure 14.86 Drug Adherence Enhancement Market for Smart Blister Packs in Asia-Pacific, 2018-2030 (Units, Million)
Figure 14.87 Drug Adherence Enhancement Market for Smart Blister Packs in Rest of the World, 2018-2030 (Units, Million)
Figure 14.88 Drug Adherence Enhancement Market for Other Type of Products, 2018-2030 (Units, Million)
Figure 14.89 Drug Adherence Enhancement Market for Other Type of Products in North America, 2018-2030 (Units, Million)
Figure 14.90 Drug Adherence Enhancement Market for Other Type of Products in Europe, 2018-2030 (Units, Million)
Figure 14.91 Drug Adherence Enhancement Market for Other Type of Products in Asia-Pacific, 2018-2030 (Units, Million)
Figure 14.92 Drug Adherence Enhancement Market for Other Type of Products in Rest of the World, 2018-2030 (Units, Million)
Figure 14.93 Drug Adherence Enhancement Market for Metabolic Disorders, 2018-2030 (USD Billion)
Figure 14.94 Drug Adherence Enhancement Market for Metabolic Disorders in North America, 2018-2030 (USD Billion)
Figure 14.95 Drug Adherence Enhancement Market for Metabolic Disorders in Europe, 2018-2030 (USD Billion)
Figure 14.96 Drug Adherence Enhancement Market for Metabolic Disorders in Asia-Pacific, 2018-2030 (USD Billion)
Figure 14.97 Drug Adherence Enhancement Market for Metabolic Disorders in Rest of the World, 2018-2030 (USD Billion)
Figure 14.98 Drug Adherence Enhancement Market for Cardiovascular Disorders, 2018-2030 (USD Billion)
Figure 14.99 Drug Adherence Enhancement Market for Cardiovascular Disorders in North America, 2018-2030 (USD Billion)
Figure 14.100 Drug Adherence Enhancement Market for Cardiovascular Disorders in Europe, 2018-2030 (USD Billion)
Figure 14.101 Drug Adherence Enhancement Market for Cardiovascular Disorders in Asia-Pacific, 2018-2030 (USD Billion)
Figure 14.102 Drug Adherence Enhancement Market for Cardiovascular Disorders in Rest of the World, 2018-2030 (USD Billion)
Figure 14.103 Drug Adherence Enhancement Market for Respiratory Disorders, 2018-2030 (USD Billion)
Figure 14.104 Drug Adherence Enhancement Market for Respiratory Disorders in North America, 2018-2030 (USD Billion)
Figure 14.105 Drug Adherence Enhancement Market for Respiratory Disorders in Europe, 2018-2030 (USD Billion)
Figure 14.106 Drug Adherence Enhancement Market for Respiratory Disorders in Asia-Pacific, 2018-2030 (USD Billion)
Figure 14.107 Drug Adherence Enhancement Market for Respiratory Disorders in Rest of the World, 2018-2030 (USD Billion)
Figure 14.108 Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders, 2018-2030 (USD Billion)
Figure 14.109 Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in North America, 2018-2030 (USD Billion)
Figure 14.110 Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in Europe, 2018-2030 (USD Billion)
Figure 14.111 Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in Asia-Pacific, 2018-2030 (USD Billion)
Figure 14.112 Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in Rest of the World, 2018-2030 (USD Billion)
Figure 14.113 Drug Adherence Enhancement Market for Other Disorders, 2018-2030 (USD Billion)
Figure 14.114 Drug Adherence Enhancement Market for Other Disorders in North America, 2018-2030 (USD Billion)
Figure 14.115 Drug Adherence Enhancement Market for Other Disorders in Europe, 2018-2030 (USD Billion)
Figure 14.116 Drug Adherence Enhancement Market for Other Disorders in Asia-Pacific, 2018-2030 (USD Billion)
Figure 14.117 Drug Adherence Enhancement Market for Other Disorders in Rest of the World, 2018-2030 (USD Billion)
Figure 14.118 Drug Adherence Enhancement Market for Metabolic Disorders, 2018-2030 (Units, Million)
Figure 14.119 Drug Adherence Enhancement Market for Metabolic Disorders in North America, 2018-2030 (Units, Million)
Figure 14.120 Drug Adherence Enhancement Market for Metabolic Disorders in Europe, 2018-2030 (Units, Million)
Figure 14.121 Drug Adherence Enhancement Market for Metabolic Disorders in Asia-Pacific, 2018-2030 (Units, Million)
Figure 14.122 Drug Adherence Enhancement Market for Metabolic Disorders in Rest of the World, 2018-2030 (Units, Million)
Figure 14.123 Drug Adherence Enhancement Market for Cardiovascular Disorders, 2018-2030 (Units, Million)
Figure 14.124 Drug Adherence Enhancement Market for Cardiovascular Disorders in North America, 2018-2030 (Units, Million)
Figure 14.125 Drug Adherence Enhancement Market for Cardiovascular Disorders in Europe, 2018-2030 (Units, Million)
Figure 14.126 Drug Adherence Enhancement Market for Cardiovascular Disorders in Asia-Pacific, 2018-2030 (Units, Million)
Figure 14.127 Drug Adherence Enhancement Market for Cardiovascular Disorders in Rest of the World, 2018-2030 (Units, Million)
Figure 14.128 Drug Adherence Enhancement Market for Respiratory Disorders, 2018-2030 (Units, Million)
Figure 14.129 Drug Adherence Enhancement Market for Respiratory Disorders in North America, 2018-2030 (Units, Million)
Figure 14.130 Drug Adherence Enhancement Market for Respiratory Disorders in Europe, 2018-2030 (Units, Million)
Figure 14.131 Drug Adherence Enhancement Market for Respiratory Disorders in Asia-Pacific, 2018-2030 (Units, Million)
Figure 14.132 Drug Adherence Enhancement Market for Respiratory Disorders in Rest of the World, 2018-2030 (Units, Million)
Figure 14.133 Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders, 2018-2030 (Units, Million)
Figure 14.134 Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in North America, 2018-2030 (Units, Million)
Figure 14.135 Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in Europe, 2018-2030 (Units, Million)
Figure 14.136 Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in Asia-Pacific, 2018-2030 (Units, Million)
Figure 14.137 Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in Rest of the World, 2018-2030 (Units, Million)
Figure 14.138 Drug Adherence Enhancement Market for Other Disorders, 2018-2030 (Units, Million)
Figure 14.139 Drug Adherence Enhancement Market for Other Disorders in North America, 2018-2030 (Units, Million)
Figure 14.140 Drug Adherence Enhancement Market for Other Disorders in Europe, 2018-2030 (Units, Million)
Figure 14.141 Drug Adherence Enhancement Market for Other Disorders in Asia-Pacific, 2018-2030 (Units, Million)
Figure 14.142 Drug Adherence Enhancement Market for Other Disorders in Rest of the World, 2018-2030 (Units, Million)
Figure 14.143 Drug Adherence Enhancement Market for Products Intended for Oral Medications, 2018-2030 (USD Billion)
Figure 14.144 Drug Adherence Enhancement Market for Products Intended for Oral Medications in North America, 2018-2030 (USD Billion)
Figure 14.145 Drug Adherence Enhancement Market for Products Intended for Oral Medications in Europe, 2018-2030 (USD Billion)
Figure 14.146 Drug Adherence Enhancement Market for Products Intended for Oral Medications in Asia-Pacific, 2018-2030 (USD Billion)
Figure 14.147 Drug Adherence Enhancement Market for Products Intended for Oral Medications in Rest of the World, 2018-2030 (USD Billion)
Figure 14.148 Drug Adherence Enhancement Market for Products Intended for Injectables, 2018-2030 (USD Billion)
Figure 14.149 Drug Adherence Enhancement Market for Products Intended for Injectables in North America, 2018-2030 (USD Billion)
Figure 14.150 Drug Adherence Enhancement Market for Products Intended for Injectables in Europe, 2018-2030 (USD Billion)
Figure 14.151 Drug Adherence Enhancement Market for Products Intended for Injectables in Asia-Pacific, 2018-2030 (USD Billion)
Figure 14.152 Drug Adherence Enhancement Market for Products Intended for Injectables in Rest of the World, 2018-2030 (USD Billion)
Figure 14.153 Drug Adherence Enhancement Market for Products Intended for Inhalable Medications, 2018-2030 (USD Billion)
Figure 14.154 Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in North America, 2018-2030 (USD Billion)
Figure 14.155 Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in Europe, 2018-2030 (USD Billion)
Figure 14.156 Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in Asia-Pacific, 2018-2030 (USD Billion)
Figure 14.157 Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in Rest of the World, 2018-2030 (USD Billion)
Figure 14.158 Drug Adherence Enhancement Market for Products Intended for Other Medications, 2018-2030 (USD Billion)
Figure 14.159 Drug Adherence Enhancement Market for Products Intended for Other Medications in North America, 2018-2030 (USD Billion)
Figure 14.160 Drug Adherence Enhancement Market for Products Intended for Other Medications in Europe, 2018-2030 (USD Billion)
Figure 14.161 Drug Adherence Enhancement Market for Products Intended for Other Medications in Asia-Pacific, 2018-2030 (USD Billion)
Figure 14.162 Drug Adherence Enhancement Market for Products Intended for Other Medications in Rest of the World, 2018-2030 (USD Billion)
Figure 14.163 Drug Adherence Enhancement Market for Products Intended for Oral Medications, 2018-2030 (Units, Million)
Figure 14.164 Drug Adherence Enhancement Market for Products Intended for Oral Medications in North America, 2018-2030 (Units, Million)
Figure 14.165 Drug Adherence Enhancement Market for Products Intended for Oral Medications in Europe, 2018-2030 (Units, Million)
Figure 14.166 Drug Adherence Enhancement Market for Products Intended for Oral Medications in Asia-Pacific, 2018-2030 (Units, Million)
Figure 14.167 Drug Adherence Enhancement Market for Products Intended for Oral Medications in Rest of the World, 2018-2030 (Units, Million)
Figure 14.168 Drug Adherence Enhancement Market for Products Intended for Injectables, 2018-2030 (Units, Million)
Figure 14.169 Drug Adherence Enhancement Market for Products Intended for Injectables in North America, 2018-2030 (Units, Million)
Figure 14.170 Drug Adherence Enhancement Market for Products Intended for Injectables in Europe, 2018-2030 (Units, Million)
Figure 14.171 Drug Adherence Enhancement Market for Products Intended for Injectables in Asia-Pacific, 2018-2030 (Units, Million)
Figure 14.172 Drug Adherence Enhancement Market for Products Intended for Injectables in Rest of the World, 2018-2030 (Units, Million)
Figure 14.173 Drug Adherence Enhancement Market for Products Intended for Inhalable Medications, 2018-2030 (Units, Million)
Figure 14.174 Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in North America, 2018-2030 (Units, Million)
Figure 14.175 Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in Europe, 2018-2030 (Units, Million)
Figure 14.176 Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in Asia-Pacific, 2018-2030 (Units, Million)
Figure 14.177 Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in Rest of the World, 2018-2030 (Units, Million)
Figure 14.178 Drug Adherence Enhancement Market for Products Intended for Other Medications, 2018-2030 (Units, Million)
Figure 14.179 Drug Adherence Enhancement Market for Products Intended for Other Medications in North America, 2018-2030 (Units, Million)
Figure 14.180 Drug Adherence Enhancement Market for Products Intended for Other Medications in Europe, 2018-2030 (Units, Million)
Figure 14.181 Drug Adherence Enhancement Market for Products Intended for Other Medications in Asia-Pacific, 2018-2030 (Units, Million)
Figure 14.182 Drug Adherence Enhancement Market for Products Intended for Other Medications in Rest of the World, 2018-2030 (Units, Million)
Figure 15.1 Overall Drug Adherence Enhancement Market, Conservative, Base and Optimistic Scenarios, 2018 and 2030

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • 3M
  • Capital Angels
  • Excell Partners
  • KCRise Fund
  • Novartis
  • SHL Group
  • MORE

Research Methodology

The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts’ views

While the focus has been on forecasting the market over the coming 12 years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines:

Chapter 2 provides an executive summary of the insights captured during our research. It offers a high-level view on the likely evolution of smart / connected devices that are being developed for improving medication adherence among patients.

Chapter 3 provides a general overview about medication adherence and the various methods / parameters used to measure and track patient compliance to prescribed therapeutic regimens. It also includes brief discussion on various types of non-adherence to therapy exhibited by patients and different factors that are considered to be responsible for such practices. In addition, the chapter features a detailed discussion on how non-adherence to therapy is impacting the health of patients and the overall healthcare industry. Further, it includes a brief discussion on various traditional and modern strategies for overcoming poor therapy adherence in patients. The chapter also provides information on the different initiatives that have been undertaken by various organizations to promote medication adherence.

Chapter 4 includes information on over 60 smart drug delivery devices that are either commercialized or under different stages of development for improving medication adherence. The chapter includes the information on the developer companies and the type of smart drug delivery product they offer; these include smart inhalers, smart injectors, smart wearable injectors, smart pills and other such devices. In addition, the chapter includes an analysis based on key product specifications, namely audio / visual reminders, connectivity features (USB connection, Bluetooth and / or cellular network), availability of companion mobile application, and companion web portal, data storage / cloud platform options and availability of battery backup / rechargeable battery.

Chapter 5 includes information on over 70 smart accessory devices that are either commercialized or under different stages of development for improving medication adherence. The chapter includes information on the developer companies and the type of smart accessory product they offer; these include smart medication dispensers, smart pill bottles / caps, smart pill boxes, smart blister packs and others. In addition, the chapter includes an analysis on key product specifications, namely audio / visual reminders, connectivity features (USB connection, Bluetooth, Wi-Fi and / or cellular network), availability of companion mobile application, and companion web portal, data storage / cloud platform options and availability of battery backup / rechargeable battery. Further, the chapter includes a brief overview on compliance packaging and a list of key players with expertise in this domain.

Chapter 6 provides information on various guidelines issued by regulatory authorities to govern the development and approval of combination products (drugs and smart devices) across different geographical regions such as North America, Europe, Latin America, Asia Pacific and the Middle East.

Chapter 7 features detailed profiles of some of the leading stakeholders in the smart drug delivery systems market. Each profile includes a brief overview of the company, financial information (if available), details related to its products / offerings, clinical trial results, recent developments and a comprehensive future outlook.

Chapter 8 features detailed profiles of some of the leading stakeholders in the smart accessory systems market. Each profile includes a brief overview of the company, financial information (if available), details related to its products / offerings, clinical trial results, recent developments and a comprehensive future outlook.

Chapter 9 features case studies on the most common disease indications across metabolic disorders, respiratory disorders and autoimmune disorders. Each case study features a detailed description of the disease, its epidemiology, an overview of the economic burden imposed due to non-adherence to prescribed treatments for the disease and history of drug development along with the evolution of delivery devices / strategies focused on improving therapy adherence.

Chapter 10 presents a product competitiveness analysis of all connected smart drug delivery systems and smart accessory systems on the basis of supplier power and key product specifications. The analysis was designed to enable stakeholder companies to compare their existing capabilities within and beyond their respective peer groups and identify opportunities to achieve a competitive edge in the industry.

Chapter 11 provides information on the funding and investments that have been made in both smart drug delivery systems and smart accessory systems in the recent past. The chapter includes details on various types of capital investments, such as seed financing, venture funding, debt financing and grants, received by companies, highlighting the growing interest of the venture capital community and other strategic investors in this domain.

Chapter 12 features an analysis of the recent collaborations and partnerships that have been inked amongst players in this market, covering several partnership models, namely acquisitions, treatment optimization agreements, distribution agreements, manufacturing and supply agreements, product improvement agreements, product development agreements, product commercialization agreements, licensing agreements, service alliances and others, that have been adopted by industry stakeholders in this domain. It includes a world map representation of all the deals inked in this field in the period 2010-2018, highlighting both intercontinental and intracontinental partnership activity.

Chapter 13 provides a brief overview of the increasing prominence of mobile applications in the healthcare industry and the various regulations laid down by the USFDA for such applications. It includes a list of applications that are available at Google Play Store for helping patients adhere to prescribed medication regimens. The chapter also provides information on the various articles / publications, featuring results of studies aimed to demonstrate the benefits of using mobile applications for improving medication adherence among patients.

Chapter 14 presents a comprehensive market forecast, highlighting the future potential of the market till 2030 based on multiple parameters, such as prices of novel solutions, indication / region specific adoption trends, and competitive landscape. We have provided an informed estimate on the likely evolution of smart drug delivery devices and smart accessory devices. In addition, we have segmented the market by type of product (smart inhalers, smart injectors, smart wearable injectors, smart pills, smart medication dispensers, smart pill bottles / caps and boxes, smart blister packs and others), therapeutic areas (metabolic disorders, cardiovascular disorders, neurological and central nervous system related disorders, respiratory disorders and others), route of administration (oral, injectable, inhalable and others) and geography (North America, Europe, Asia-Pacific and rest of the world).

Chapter 15 summarizes the overall report. The chapter provides a list of the key takeaways and presents our independent opinion on the medication adherence market, specific to smart drug delivery systems and smart accessory systems, based on the research and analysis described in the previous chapters.

Chapter 16 is a collection of interview transcripts of the discussions that were held with key stakeholders in this market. The chapter provides details of interviews held with Bernard Vrijens (Chief Executive Officer, AARDEX Group), Spencer Waugh (Chief Executive Officer, AceAge), Josh Stein (Chief Executive Officer, AdhereTech), Duilio Macchi (Chief Executive Officer, Amiko Digital Health), Gaurav Patel (Chief Technical Officer, Cognita Labs), Tina Valbh (Strategy and Business Development (Advisor), etectRx), Jonathan Sacks (Chief Executive Officer and Chairman, PharmAdva), Timo Heikkilä (Co-Founder and Chief Operating Officer, Popit Technologies), Moore Greenberg (Founder, Wealth Taxi) and Anonymous (Small-sized company)

Chapter 17 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 18 is an appendix, which provides the list of companies and organizations mentioned in the report.

Note: Product cover images may vary from those shown
5 of 4
  • 3M
  • 5AM Ventures
  • 7wire Ventures
  • 91streets Media Technologies
  • AARDEX Group
  • AARP
  • Abbott
  • Abiogenix
  • AceAge
  • Acintyo
  • Acta Distribution
  • ActiveCare
  • Adams Street Partners
  • AdhereTech
  • Adherium
  • Administración Nacional de Medicamentos, Alimentosy Tecnología Médica
  • Advent Venture Partners
  • Aerobit Health
  • AeroSonix
  • Aguettant
  • Agência Nacional de Vigilância Sanitária (National Health Surveillance Agency)
  • Air Liquide Healthcare
  • AIRBRIO
  • Airnest
  • Allscripts
  • Altran
  • Amarutek
  • Amazon
  • AMC Health
  • American Academy of Allergy, Asthma and Immunology
  • American Heart Association
  • Amerigroup
  • Amgen
  • Amiko Digital Health
  • ANTARGYAN CLOUDWORKS
  • ApnaCare India
  • Apollo Diabetes Care Management
  • Apolotus Health Solution
  • Apoteket
  • App Singularity
  • AppAttic
  • Appgraid Apps
  • AppQuik
  • AppTrailz
  • Aptar Pharma
  • Area9 Innovation
  • Arthur Health
  • Artmedus
  • ARTORG Center
  • AS PHARM SOFT
  • Asheville Angels
  • Asho Soft Tech
  • Asset Management Ventures
  • Asthma and Respiratory Foundation New Zealand
  • AstraZeneca
  • AT&T
  • Aterica Digital Health
  • August Faller Group
  • Auriga Partners
  • Australasian Medical & Scientific
  • Austrian Chamber of Pharmacists
  • Automated Security Alert
  • Aventyn
  • Avery Dennison Medical Solutions
  • Avnet Integrated Solutions
  • Baviux
  • Bayer
  • Becton Dickinson
  • BERG
  • Bigfoot Biomedical
  • BioAdvance
  • BioAssist
  • BIOCORP
  • BioMark Health
  • BioScience Managers
  • BIVA
  • Blackberry
  • BlackPearls
  • Blueprint Health
  • Boehringer Ingelheim
  • Bosch
  • Brain Tech
  • Brainovations Education Excellence
  • Breed Reply
  • Butterfly Ventures
  • C Square Info Solutions
  • C-Square Info Solutions
  • C3HealthLink
  • caiocrol
  • California HealthCare Foundation
  • California Highlands Addiction Treatment
  • Cambridge Consultants
  • Cambridge Enterprise
  • Canada Innovation Acceleration Investment
  • Capital Angels
  • Capital Royalty Partners II
  • Cardinal Health
  • CareCentra
  • CareConsult
  • CareZone
  • Catalent Pharma Solutions
  • Celgene
  • Cellnovo
  • Cenduit
  • Centers for Disease Control and Prevention
  • Centers for Medicare & Medicaid Services
  • Central Drugs Standard Control Organization
  • Centric Health
  • Chalmers Ventures
  • CheckTheMeds Technology
  • Children's Hospital of Philadelphia
  • China Food and Drug Administration
  • CHORDAS
  • Chronicare
  • Cigna Health Insurance
  • Cincinnati Children's Hospital Medical Center
  • Circadian Design
  • Clifton R Farris
  • CML Advocates Network
  • Cognita Labs
  • Cognitive Healthcare
  • Cohero Health
  • Colbert Packaging
  • Comisión Federal para la Protección contra Riesgos Sanitarios
  • Common Sensing
  • Community Care Network of Virginia
  • Companion Medical
  • Compliance Meds Technologies
  • Confrérie Clinique
  • Connecticut Children's Medical Center
  • Core Mobile
  • Credit Agricole Private Equity
  • Crux Product Design
  • CSL Behring
  • CUCO Health
  • CuePath Innovation
  • Curatio
  • Curis
  • Cyft
  • DayaMed
  • Debiotech
  • Decision Machines
  • DeepBench
  • Delphi Ventures
  • Desert Oasis Healthcare
  • DeskShare
  • Dexcom
  • Diabeloop
  • Diasend
  • Digital Pharmacist
  • Diplomat Pharmacy
  • Disetronic Group
  • Dispill-USA
  • DistriMedic
  • DocRoSh Health
  • Domain Associates
  • Dosecast
  • DoseCue
  • DoseSmart
  • DOTh Solutions
  • Douglas Pharmaceuticals
  • Drug Package
  • Duke University
  • DYN Diagnostics
  • E Ink
  • EcoloPharm
  • Edmond de Rothschild
  • Elcam Drug Delivery Devices (E3D)
  • Eli Lilly
  • Elkstone Capital Partners
  • EMedStore Pharma IT
  • emocha Mobile Health
  • Emperra E-Health Technologies
  • Enable Injections
  • Enercon Technologies
  • EnvoyHealth
  • Essex Woodlands
  • etectRx
  • ETHIO APPS
  • Eularis
  • European Investment Bank
  • European Medicines Agency
  • Evalan
  • Everwell Health Solutions
  • Everwin Precision Technology
  • Evondos
  • Excell Partners
  • Experts in Communications and Connectivity Technology (ECCT)
  • Express Scripts
  • Fagor Healthcare
  • Fedefarma
  • Fidelity International
  • FindAir
  • Fletcher Spaght Ventures
  • Flex
  • Forbion Capital Partners
  • Frost & Sullivan
  • GalileoMD
  • Gecko Health Innovations
  • GenieMD
  • Genome BC
  • GIS Strategic Ventures
  • GlaxoSmithKline
  • Global Emerging Markets Group
  • Gloria Pharmaceuticals
  • GlucoRx
  • GoodCare Pharma
  • GoodRx
  • GoodVent Beteiligungsmanagement
  • GoSmart
  • H&T Presspart
  • H&Y Apps
  • Hackensack Meridian Health
  • HAP Innovations
  • Haselmeier
  • HCL Technologies
  • Health Bot
  • Health Canada
  • Health Care Originals
  • Health Department of Oslo
  • Health Mission
  • Health Monitor
  • Health's Angel
  • HealthBeacon
  • Healthbox
  • HealthCare Ventures
  • Healthcom
  • Healtheoz
  • Healthio
  • HealthPrize Technologies
  • Heitkamp & Thumann Group
  • Helmer Scientific
  • Hepatitis Victoria
  • HERO Health
  • Hexoskin
  • Hikma Ventures
  • Home Diagnostics
  • HP Labs
  • HTC
  • Human API
  • Humana
  • IAP Labs
  • IDEAL LIFE
  • ImageWare Systems
  • ImagineCare
  • Immunex
  • Information Mediary
  • Innospence
  • Innovation Zed
  • INRange Systems
  • Inspirit Innovations
  • Insulin Pump Hellas
  • Intelligent Devices SEZC
  • Intelligent Product Solutions
  • Intent Solutions
  • International Diabetes Federation
  • International Federation of Pharmaceutical Manufacturers and Associations
  • Intigate Technologies
  • Investitionsbank des Landes Brandenburg
  • Irody
  • IRWAA
  • iSense
  • ITmedicus
  • Itochu
  • IVAX
  • Jabil
  • Janssen Pharmaceutica
  • JDRF
  • Jiangsu Delfu Medical Device
  • Jones Packaging
  • Joslin Diabetes Center
  • Journey Health Labs
  • JVS Technologies
  • K-svets
  • Kaiser Permanente Ventures
  • KCRise Fund
  • Keystone Folding Box
  • Konkuk University
  • Korl Medical Center
  • Kreos Capital
  • Kuwait Investment Authority
  • Life Integrating Technologies and Experiences (LITE)
  • Life Sciences Angel Network
  • LifeMatters
  • LloydsPharmacy
  • Lohmann Therapie Systeme
  • lool Ventures
  • Lowcountry Angels
  • LoyAlerts
  • LSDinfotech
  • Luz Saúde
  • M Ventures
  • M2M Datasmart
  • Maangata Apps
  • Maccabi Healthcare Services
  • Mail-Meds
  • Maj Invest Equity
  • Manchac Technologies
  • Mango Health
  • Manrex
  • Manyeta
  • MAP Health Management
  • Marketaro
  • MassChallenge
  • Maxerence
  • McKesson
  • MeadWestvaco
  • MedApps
  • MedControl Technologies
  • MedCrypt
  • Medexpert
  • Medical International Research
  • Medical Research Institute of New Zealand
  • Medical Specialties Australia
  • Medication Solutions
  • Medicine-On-Time
  • Medico Pak
  • Medicom Innovation Partner
  • MedicPen
  • Medimate
  • Medipense
  • Medisafe
  • MedMinder Systems
  • Medocity
  • MedPak Pharmacy
  • MedReady
  • MedSmart
  • Medtronic
  • Medtrum
  • MENA Apps
  • Merck
  • Metro Health
  • Mevia
  • MicroHealth
  • Ministry of Food and Drug Safety
  • Ministry of Health, Labour and Welfare
  • MivaTek Smart Connect
  • Molina Healthcare
  • Montuno Software
  • Mount Sinai Health System
  • Movi
  • MphRx
  • Multiframes
  • Mylan
  • MyMeds
  • MyTherapy
  • NantHealth
  • Nath IT Solutions
  • National Competent Authority
  • National Consumers League
  • National Institute of Mental Health (NIMH)
  • National Institutes of Health
  • Navia Life Care
  • NaviMed
  • NBGI Ventures
  • NECTEC
  • Nemera
  • NESTA
  • Nestlé Health Science
  • New Directions Technology Consulting
  • New World Health
  • New Zealand Medical & Scientific
  • NexusLink Services
  • nGageIT Digital Medicine
  • Noble International
  • NOPII
  • Novalab Ibérica
  • Novartis
  • Novo Nordisk
  • Now Healthcare Group
  • NPS MedicineWise
  • Octopus Ventures
  • Office of the National Coordinator for Health Information Technology Omnicell
  • Omron Healthcare
  • One Drop
  • Onward Care Technologies
  • Oracle Health Sciences
  • Orbita
  • ORI Healthcare Fund
  • Otsuka Pharmaceutical
  • Oxford Finance
  • Oyster Capital Partners
  • P5 Health Ventures
  • Palladio Group
  • Parata Systems
  • Partners HealthCare
  • PatientPartner
  • PBJ Capital
  • Pear Therapeutics
  • Pegasystems
  • Peppermint VenturePartners
  • PhableCare
  • Pharmacell Medication Systems
  • Pharmaceutical and Medical Devices Agency
  • PharmAdva
  • PharmaSens
  • PharmRight
  • Philips
  • Phillips-Medisize
  • Phoenix Healthcare
  • Picomol Healthcare
  • PillDrill
  • Pillo Health
  • PillPack
  • Pitango Venture Capital
  • Play-it Health
  • PMA Pharmacy
  • Poliweb Graphics
  • Popit
  • Portal Instruments
  • Practo
  • Prescription Notification Group
  • Prescription Solutions
  • ProCare Rx
  • Propeller Health
  • Proteus Digital Health
  • PRPL
  • Qualcomm Life
  • Quantum Pharmaceutical
  • Quido Healthcare Services
  • QuiO Technologies
  • Quizora Media
  • Raffles Medical Group
  • Ramtin Software Solutions
  • Raneem Technologies
  • Recovery Centers of America
  • RemindTrac
  • Renata
  • Research Institute of the McGill University Health Centre
  • Resolve Digital Health
  • Respia
  • Rex Medical
  • Risk Cooperative
  • Robert Bosch Venture Capital
  • Roche
  • RockTenn
  • Rubin Medical
  • RxAdvance
  • RxNetworks
  • RXVIP Concierge
  • Safeguard Scientifics
  • Safeway
  • Sagentia
  • Samsung
  • Samsung NEXT
  • Sanner Group
  • Sanofi
  • Sanofi-Sunrise
  • Saudi Food and Drug Authority
  • Schreiner MediPharm
  • SCRA Technology
  • Second Technology Capital Investors
  • SentiCare
  • Seoul National University
  • Serendipity Partners
  • SHL Group
  • Silicon Valley Bank
  • Simplified APP Solutions
  • Sino Portfolio
  • Sinwho
  • SmarterHealth TechServe
  • Smartgateways
  • Smiths Medical
  • Smooth Apps Studio
  • SMRxT
  • Social Capital
  • Soft Industry Alliance
  • Sonceboz
  • SOOIL Development
  • South Carolina Angel Network
  • Spartanburg Angels
  • Spring Ridge Ventures
  • Sprint
  • Spyzar Studios
  • SR One
  • St. Helena Health
  • St. Jude Medical
  • STAAR Alert
  • Sunrise Labs
  • SuperAndroidApp
  • Swanhill Capital
  • Syqe Medical
  • Takeda Pharmaceutical
  • Tandem Diabetes Care
  • TCGRx
  • Techizer Tech Solutions
  • Tekes
  • TerraNovita
  • Teva Pharmaceutical
  • The Carlyle Group
  • The Cyto Cord Group
  • The Finnish Funding Agency for Technology and Innovation
  • The Kroger
  • Therapeutic Goods Administration
  • Three Leaf Ventures
  • Tidepool
  • Tillotts Pharma
  • TimerCap
  • Tinylogics
  • Tonghua Dongbao Pharmaceutical
  • TowerView Health
  • TPG Biotech
  • Triad HealthCare Network
  • Tricella
  • Trinnovate Ventures
  • TriVentures
  • TypeZero Technologies
  • UNICUS HealthReach
  • United Family Healthcare
  • United States Food and Drug Administration
  • UnitedHealthcare
  • University of Arkansas for Medical Sciences
  • University of Cambridge
  • University of Pittsburgh Medical Center
  • University of Toronto
  • Urtech Manufacturing
  • Vaica
  • Valtronic
  • Vectura Group
  • Verizon Investments
  • Virbac
  • Vishnu Global Services
  • Vitalus Health
  • Walgreens
  • Waterline Ventures
  • Wcre8tive App Developer
  • Wealth Taxi
  • Web Coast Apps
  • Welkin Health
  • West Pharmaceutical Services
  • WestRock
  • Whisper Arts
  • WMM
  • World Allergy Organization
  • World Health Organization
  • WorldMedic
  • Wyeth-Ayerst Pharmaceuticals
  • Xcenda
  • Xhale
  • Ximedica
  • XINK Laboratories
  • YOURmeds
  • YPSOMED
  • Zaffre Investments
  • Zibdy
  • Zipit Wireless
Note: Product cover images may vary from those shown
Adroll
adroll